NanoViricides (NNVC) 10-Q/A 23 Feb 15 2015 Q1 Quarterly report (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Sep. 30, 2014	Nov. 14, 2014
Document Information [Line Items]
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1379006
Current Fiscal Year End Date	-24
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q/A
Amendment Flag	TRUE
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015
Amendment Description	NanoViricides, Inc. is filing this Amendment to its Quarterly Report on Form 10-Q for the period ending September 30, 2014, originally filed on November 14, 2014 (the “Original Filing”), to amend and restate our previously issued financial statements and the related disclosures in the Original Filing. This Form 10-Q/A supersedes and replaces in its entirety the Original Filing. During the preparation of the Company’s Quarterly Report on Form 10-Q for the period ending December 31, 2014, the Company and the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) identified an accounting error in the financial statements as of June 30, 2014. The restatement is the result of our reclassification attributable to the accounting for derivative functions contained in the anti-dilution provisions in certain warrants issued in connection with the company’s issuances of registered direct offerings. Specifically, the warrants contained certain anti-dilution ratchet provisions that provided for an adjustment to the exercise price of the warrants if the company issued any stock equivalent securities at a lower price in the future while the option was still outstanding. The Company determined that the error caused a material understatement of its derivative liability for the quarterly period ended June 30, 2014. In addition, we also have provided disclosure regarding the impact of the restatement on the adequacy of our internal control over financial reporting and disclosure controls and procedures for the relevant restatement periods in Part I, Item 4. Controls and Procedures. For a more detailed explanation of these matters and resulting restatements, please see Note 2 to the Financial Statements - Restatement of Previously Issued Financial Statements. Unless expressly noted otherwise, the disclosures in this Annual Report continue to speak as of the date of the Original Filing, and do not reflect events occurring after the filing of the Original Filing.
Document Period End Date	30-Sep-14
Entity Common Stock, Shares Outstanding		57,106,568

Balance_Sheets

Balance Sheets (USD $)	Sep. 30, 2014	Jun. 30, 2014
CURRENT ASSETS:
Cash and cash equivalents	$41,120,652	$36,696,892
Prepaid expenses	59,099	108,089
Prepaid expenses - related parties	424,402	709,221
Other current assets	0	150,000
Total Current Assets	41,604,153	37,664,202
PROPERTY AND EQUIPMENT
Property and equipment	7,299,254	6,736,742
Accumulated depreciation	-1,291,318	-1,239,986
Property and equipment, net	6,007,936	5,496,756
TRADEMARK
Trademark	458,954	458,954
Accumulated amortization	-52,889	-50,696
Trademark, net	406,065	408,258
SECURITY DEPOSIT	1,000,000	1,000,000
Total Assets	49,018,154	44,569,216
CURRENT LIABILITIES:
Accounts payable	155,978	376,446
Accounts payable - related parties	331,448	758,676
Accrued expenses	265,463	91,838
Total Current Liabilities	752,889	1,226,960
LONG TERM LIABILITIES:
Debentures payable	0	5,000,000
Total Long Term Liabilities	16,076,149	19,972,953
Total Liabilities	16,829,038	21,199,913
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY:
Common stock, $0.001 par value; 85,714,285 shares authorized;56,535,135 and 54,620,993 shares issued and outstanding, respectively	56,535	54,621
Additional paid-in capital	83,178,895	75,212,888
Accumulated deficit	-51,049,703	-51,901,400
Total Stockholders’ Equity	32,189,116	23,369,303
Total Liabilities and Stockholders’ Equity	49,018,154	44,569,216
Warrant [Member]
LONG TERM LIABILITIES:
Derivative Liability	4,558,581	5,235,682
Series B Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	4,195,296	4,037,568
Derivative Liability	3,785,385	5,699,703
Series C Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	2,083,765	0
Derivative Liability	1,453,122	0
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Preferred stock	3,389	3,194
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Preferred stock	0	0
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Preferred stock	$0	$0

Balance_Sheets_Parenthetical

Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2014	Jun. 30, 2014
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	85,714,285	85,714,285
Common stock, shares issued	56,535,135	54,620,993
Common stock, shares, outstanding	56,535,135	54,620,993
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	3,387,795	3,193,079
Preferred stock, shares outstanding	3,387,795	3,193,079
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
OPERATING EXPENSES
Research and development	$811,107	$1,174,221
Refund credit research and development costs	0	0
General and administrative	876,026	714,561
Total operating expenses	1,687,133	1,888,782
LOSS FROM OPERATIONS	-1,687,133	-1,888,782
OTHER INCOME (EXPENSE):
Interest income, net	39,323	9,560
Interest expense	-245,000	-120,986
Discount on convertible debentures	-273,218	-135,481
Beneficial conversion feature of convertible debentures	0	0
Change in fair market value of derivatives	3,017,725	-4,425,833
Other income (expense), net	2,538,830	-4,672,740
LOSS BEFORE INCOME TAXES	851,697	-6,561,522
INCOME TAX PROVISION	0	0
NET INCOME (LOSS)	$851,697	($6,561,522)
NET INCOME (LOSS) PER COMMON SHARE - BASIC AND DILUTED: (in dollars per share)	$0.02	($0.14)
Weighted average common shares outstanding - basic and diluted (in shares)	55,576,200	47,672,029

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Subscription Received [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]
Balance at Jun. 30, 2013	$8,009,652	$47,026	$46,259,420	$0	($38,299,784)	$2,990	$0	$0
Balance (in shares) at Jun. 30, 2013		47,026,173				2,990,000	0	0
Warrants issued to Scientific Advisory Board, For August	106,050	0	106,050
Common shares issued for consulting and legal services, August	7,000	4	6,996
Common shares issued for consulting and legal services valued August (in shares)		3,449
Common shares issued for consulting and legal services valued For September	7,000	3	6,997
Common shares issued for consulting and legal services valued For September (in shares)		3,226
Adjustment to Additional paid in Capital	83,900		83,900
Warrants issued to Scientific Advisory Board, For November	31,552	0	31,552
Common shares issued for consulting and legal services For November	7,000	1	6,999
Common shares issued for consulting and legal services For November (in shares)		1,362
Common shares issued for consulting and legal services For December	7,001	2	6,999
Common shares issued for consulting and legal services For December (in shares)		1,383
Common shares issued for consulting and legal services For January	7,000	1	6,999
Common shares issued for consulting and legal services For January (in shares)		1,828
Warrants issued to Scientific Advisory Board, February	30,352	0	30,352
Common shares issued for consulting and legal services February	7,000	2	6,998
Common shares issued for consulting and legal services February (in shares)		1,763
Common shares issued for consulting and legal services, For March	7,000	2	6,998
Common shares issued for consulting and legal services, March (in shares)		1,397
Warrants issued to Scientific Advisory Board, May	31,895	0	31,895
Common shares issued for consulting and legal services July	7,000	4	6,996
Common shares issued for consulting and legal services July (in shares)		3,627
Shares issued in payment of Debenture interest on February	2,605,716	571	2,605,145
Shares issued in payment of Debenture interest on February (in shares)		571,429
Common shares and warrants issued in connection with private placement of common stock, September 10, 2013	10,308,996	2,945	10,306,051
Common shares and warrants issued in connection with private placement of common stock, September 10, 2013 (in shares)		2,945,428
Costs associated with sale of Securities	-113,696		-113,696
Warrants issued for commissions	113,696	0	113,696
Placement Agents Fees related to sale of Common shares and Warrants	-618,545	0	-618,545
Common Shares issued to round up fractional shares arising from private placement		6	-6
Common Shares issued to round up fractional shares arising from private placement (in shares)		5,940
Common Shares issued in connection with warrant conversion, September 25, 2013	185,624	35	185,589
Common Shares issued in connection with warrant conversion, September 25, 2013 (in shares)		35,357
Shares issued for Directors fees at $2.04 per share on September 30, 2013	11,250	6	11,244
Shares issued for Directors fees at $2.04 per share on September 30, 2013 (in shares)		5,501
Common Shares issued in connection with warrant conversion, February 6, 2014	131,250	25	131,225
Common Shares issued in connection with warrant conversion, February 6, 2014 (in shares)		25,000
Series A Preferred Shares issued for employee stock compensation at October 1, 2013	36,000	0	35,995			5
Series A Preferred Shares issued for employee stock compensation at October 1, 2013 (in shares)						5,025
Warrants issued for commissions, January 24, 2014	135,062	0	135,062
Placement Agents Fees related to sale of Common shares and Warrants on January 24, 2014	-1,201,815	0	-1,201,815
Shares issued for Directors fees at $5.01 per share on March 31, 2014	11,250	2	11,248
Shares issued for Directors fees at $5.01 per share on March 31, 2014 (in shares)		2,247
Series A Preferred Shares issued for employee stock compensation at April 30, 2014	20,896	0	20,894			2
Series A Preferred Shares issued for employee stock compensation at April 30, 2014 (in shares)		0				2,572
Costs associated with sale of Securities January 24, 2014	-135,062		-135,062
Shares issued for consulting and legal services rendered at $5.29 per share on October 31, 2013	7,000	1	6,999
Shares issued for consulting and legal services rendered at $5.29 per share on October 31, 2013 (in shares)		1,323
Common Shares issued in connection with warrant conversion, December 16, 2013	25,000	7	24,993
Common Shares issued in connection with warrant conversion, December 16, 2013 (in shares)		7,143
Shares issued for Directors fees at $5.07 per share on December 31, 2013	11,250	2	11,248
Shares issued for Directors fees at $5.07 per share on December 31, 2013 (in shares)		2,220
Series A Preferred Shares issued for employee stock compensation	192,041	0	192,020			21
Series A Preferred Shares issued for employee stock compensation (in shares)		0				20,695
Series A Preferred Shares issued for employee stock compensation at May 31, 2014	20,379	0	20,376			3
Series A Preferred Shares issued for employee stock compensation at May 31, 2014 (in shares)		0				2,572
Shares issued for consulting and legal services rendered at $4.11 per share at June 30, 2014	9,000	2	8,998
Shares issued for consulting and legal services rendered at $4.11 per share at June 30, 2014 (n shares)		2,190
Net loss	-14,106,474	0			-14,106,474
Common Shares issued in connection with warrant conversion, January 21, 2014	393,750	75	393,675
Common Shares issued in connection with warrant conversion, January 21, 2014 (in shares)		75,000
Common Stock And Warrants Issued Value During January In Connection With Private Placement	20,030,207	3,815	20,026,392
Common Stock And Warrants Issued Shares During January In Connection With Private Placement		3,815,285
Common shares issued for employee stock compensation, June	12,000	3	11,997
Common shares issued for employee stock compensation, June (in shares)		2,593
Series A Preferred Shares issued for employee stock compensation at June 30, 2014	22,902	0	22,899			3
Series A Preferred Shares issued for employee stock compensation at June 30, 2014 (in shares)		0				2,572
Series A Preferred Shares issued for employee stock compensation at June 30, 2014	1,830,796		1,830,626			170
Series A Preferred Shares issued for employee stock compensation at June 30, 2014 (in shares)		0				169,643
Shares issued for Directors fees at $4.11 per share on June 30, 2014	11,250	3	11,247
Shares issued for Directors fees at $4.11 per share on June 30, 2014 (in shares)		3,178
Restatement Adjustment	-5,740,540		-5,740,540
Common shares issued for employee stock compensation at $4.03 per share, June 30, 2014	287,860	72	287,788
Common shares issued for employee stock compensation at $4.03 per share, June 30, 2014 (in shares)		71,430
Restatement Adjustment	504,858				504,858
Shares issued for consulting and legal services rendered at 3.25 per share on April 30, 2014	9,000	3	8,997
Shares issued for consulting and legal services rendered at $3.25 per share on April 30, 2014 (in shares)		2,769
Shares issued for consulting and legal services rendered at 3.27 per share on May 31, 2014	9,000	3	8,997
Shares issued for consulting and legal services rendered at 3.27 per share on May 31, 2014 (in shares)		2,752
Balance at Jun. 30, 2014	23,369,303	54,621	75,212,888	0	-51,901,400	3,194	0	0
Balance (in shares) at Jun. 30, 2014		54,620,993				3,193,079	0	0
Warrants issued to Scientific Advisory Board, For August	22,292	0	22,292
Net loss	851,697	0			-239,070
Series A Preferred Shares issued for employee stock compensation July 31, 2014	23,634	0	23,632			2
Series A Preferred Shares issued for employee stock compensation July 31, 2014 (in shares)		0				2,572
Shares issued for consulting and legal services rendered on July 31, 2014	9,000		9,000
Shares issued for consulting and legal services rendered on July 31, 2014 (in shares)		543
Shares issued for consulting and legal services rendered on August 31, 2014	9,000	1	8,999
Shares issued for consulting and legal services rendered on August 31, 2014 (in shares)		590
Series A Preferred Shares issued for employee stock compensation at August 31, 2014	25,332	0	25,329			3
Series A Preferred Shares issued for employee stock compensation at August 31, 2014 (in shares)		0				2,572
Common Shares issued in connection with warrant conversion, August 15,2014	6,682,297	1,909	6,680,388
Common Shares issued in connection with warrant conversion, August 15,2014 (in shares)		1,909,227
Shares issued for consulting and legal services rendered on September 30, 2014	9,000	1	8,999
Shares issued for consulting and legal services rendered on September 30, 2014 (in shares)		926
Series A Preferred Shares issued for employee stock compensation at September 30, 2014	24,014	0	24,011			3
Series A Preferred Shares issued for employee stock compensation at September 30, 2014 (in shares)		0				2,572
Shares issued for Directors fees at $3.94 per share on September 30, 2014	11,250	3	11,247
Shares issued for Directors fees at $3.94 per share on September 30, 2014 (in shares)		2,856
Series A Preferred Shares issued for Debenture inerest July 2, 2014	1,152,297	0	1,152,110			187
Series A Preferred Shares issued for Debenture inerest July 2, 2014 (in shares)		0				187,000
Restatement Adjustment	1,090,767				1,090,767
Balance at Sep. 30, 2014	$32,189,116	$56,535	$83,178,895	$0	($51,049,703)	$3,389	$0	$0
Balance (in shares) at Sep. 30, 2014		56,535,135				3,387,795	0	0

Statement_of_Stockholders_Equi1

Statement of Stockholders' Equity [Parenthetical] (USD $)	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Jun. 30, 2014
Price per share of common stock issued for consulting services, July One		$1.93
Price per share of common stock issued for consulting services, August One		$2.03
Price per share of common stock issued for consulting services, September One		$2.17
Price per share of common stock issued for consulting services, February One		$3.97
Price per share of common stock issued for consulting and legal services, October		$5.29
Price per share of common stock issued for consulting and legal services, November		$5.14
Price per share of common stock issued for consulting and legal services, December		$5.01
Price per share of common stock issued for consulting and legal services, January		$5.01
Price per share of common stock issued for payment of debenture interest stock, February		$0.48
Price per share of common stock issued for employee stock compensation, March One		$4.03
Price per share of common stock issued for consulting and legal services, March	$3.83
Price per share of common stock issued for director services rendered, March		$5.01
Stock Issued During September For Director Services Rendered Price Per Share	$3.25	$2.04
Stock Issued During December For Director Services Rendered Price Per Share	$4.11	$5.07
Stock Issued During Period For Employee Stock Compensation Price Per Share For June One		$4.03
Stock Issued During Period For Director Fees Price Per Share June		$4.11

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (loss)	$851,697	($6,561,522)	($14,106,474)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Preferred shares issued for license		0
Series A Preferred shares issued as compensation	72,980	0
Common shares and warrants issued for services	38,250	32,250
Warrants granted to scientific advisory board	22,292	106,050
Depreciation	51,332	52,719
Amortization	2,193	2,193
Change in fair value of derivative liability	-3,017,725	4,425,833
Discount convertible debentures	273,218	135,481
Changes in operating assets and liabilities:
Prepaid expenses	48,990	-206,765
Prepaid expenses - Related parties	284,819
Other current assets	150,000	0
Accounts payable - trade	-220,468	144,802
Accounts payable - related parties	-427,228	429,258
Accrued expenses	173,625	115,253
NET CASH USED IN OPERATING ACTIVITIES	-1,696,025	-1,324,448
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposit	0	-1,000,000
Purchase of property and equipment	-562,512	-2,273,989
NET CASH USED IN INVESTING ACTIVITIES	-562,512	-3,273,989
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs		9,690,450
Proceeds from exercise of warrants	6,682,297	185,624
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,682,297	9,876,074
NET CHANGE IN CASH	4,423,760	5,277,637
Cash at beginning of period	36,696,892	13,923,245	13,923,245
Cash at end of period	41,120,652	19,200,882	36,696,892
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	0	0
Income tax paid	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common stock issued for services rendered	38,250	32,250
Preferred stock issued as compensation	72,980	0
Series A Preferred stock issued as discount on Debentures	1,645,606
Stock warrants granted to scientific advisory board	22,292	106,050
Stock warrants granted to brokers		$113,696

Organization_and_Nature_of_Bus

Organization and Nature of Business	3 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 - Organization and Nature of Business
	NanoViricides, Inc. was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc. which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On May 12, 2005, the corporations were merged and Edot-com.com, Inc., the Nevada corporation, became the surviving entity.
	On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.
	Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 newly issued shares of ECMM common stock resulting in an aggregate of 100,000,000 shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of 4,000 shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.
	As a result of the Exchange transaction, the former NVI stockholders held approximately 80% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of the Company by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.
	On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.
	NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour Pharma on  September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.
	On February 15, 2010 the Company executed an Additional License Agreement with TheraCour Pharma, Inc. (“TheraCour”).  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Preferred Series A do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the holder’s approval. The 2,000,000 shares were valued at the par value of $2,000 (adjusted for the reverse split).
	We focus our research and clinical programs on specific anti-viral therapeutics. The Company’s platform technology is based on novel biomimetic nanomedicine constructs, called nanoviricides®. A nanoviricide is designed to “fool” the virus into binding to the nanoviricide in the same fashion that it would bind to the host cell. Because the host cell receptor and how the virus binds to it does not change despite all the changes in the virus, the Company believes that our broad-spectrum nanoviricides should continue to work against the virus despite the viral mutations and other changes. We are seeking to add to our existing portfolio of products through our internal discovery and clinical development programs and through an in-licensing strategy.
	The Company has held a pre-IND Meeting with the US FDA for its clinical drug candidate NV-INF-1 in the FluCide™ program. The Company is developing this injectable drug (NV-INF-1) for hospitalized patients with severe influenza, including immuno-compromised patients. The Company believes that this drug may also be usable as a single-dose injection in a medical office for less severe cases of influenza. The Company has also developed an oral anti-influenza drug candidate, NV-INF-2, with a very high degree of effectiveness when taken by mouth. This may be the first ever nanomedicine that is orally active. Both of these anti-influenza therapeutic candidates are “broad-spectrum”, i.e. they are expected to be effective against most if not all types of influenzas including Bird Flu H5N1, Highly Pathogenic Influenzas (HPI/HPAI), Epidemic Influenzas such as the 2009 “swine flu” H1N1/A/2009, and Seasonal Influenzas including the recent H3N2 influenza. The Company has already demonstrated that they have significantly superior activity when compared to oseltamivir (Tamiflu®) against two unrelated influenza A subtypes, namely, H1N1 and H3N2 in a highly lethal animal model. Both of these drug candidates can be used as prophylactics to protect at-risk personnel such as health-care workers and immediate family members and caretakers of a patient.
	The Company’s broad-spectrum drug candidate for the treatment of dengue viral infections, DengueCide™, has received “orphan drug” status from both the US FDA and the European Medicines Agency (“EMA”). This orphan drug status carries with it several tax benefits and other financial equivalent incentives. Notably, in the US, orphan drug status will enable us to gain a “Priority Review Voucher” that can be applied to another drug development program or can be sold for a consideration to another pharmaceutical company, once the drug is approved. The Company has therefore prioritized its Dengue drug development program.
	The Company is also developing an anti-HIV drug. The drug candidates in this HIVCide(™) program were found to have effectiveness equal to that of a triple drug HAART cocktail therapy in the standard humanized SCID-hu Thy/Liv mouse model. Moreover, the nanoviricides were long acting. Viral load suppression continued to hold for more than four weeks after stopping HIVCide treatment. The Company believes that the strong effect and sustained effect indicate that an HIVCide can be developed as a single agent that would provide “Functional Cure” from HIV/AIDS. The Company believes that substantially all HIV virus can be cleared upon HIVCide treatment, except the integrated viral genome in latent cells. This would enable discontinuation of treatment until HIV reemerges from the latent reservoir, which may be several months without any drugs. Moreover, the Company believes that this therapy would also minimize the chances of HIV transmission. The Company is currently optimizing the anti-HIV drug candidates. These drug candidates are effective against both the R5 and X4 subtypes of HIV-1 in cell cultures. The Company believes that these drug candidates are “broad-spectrum”, i.e. they are expected to be effective against most strains and mutants of HIV, and therefore escape of mutants from our drugs is expected to be minimal.
	The Company is also developing a broad-spectrum skin cream for the treatment of oral and genital herpesvirus infections (i.e. both HSV-1 and HSV-2).
	In addition, the Company is also developing broad-spectrum eye drops that are expected to be effective against a majority of the viral infections of the external eye. Most of these viral infections are from adenoviruses or from herpesviruses. The Company has shown excellent efficacy of its drug candidates against EKC (adenoviral epidemic kerato-conjunctivitis) in an animal model. In addition, the anti-HSV drug candidates have shown excellent efficacy in cell culture studies. The Company is also developing a skin cream formulation for the treatment of herpes cold sores or genital warts. Further, the Company is also developing a broad-spectrum drug against Dengue viruses that is expected to be useful for the treatment of any of the four major serotypes of dengue viruses, including in severe cases of dengue (DSS) and dengue hemorrhagic fever (DHF). DSS and DHF are thought to be caused by prior antibodies against dengue that a patient’s body creates to fight a second unrelated dengue infection, and the second virus uses these antibodies effectively to hitch a ride into human cells, thereby causing a more severe infection than in naive patients. In addition to these six drugs in development, the Company also has research programs against Rabies virus, Ebola and Marburg viruses, and others. To date, the Company does not have any commercialized products.
	Thus, at present, the Company has six commercially important drug programs in its pipeline that have shown significant successes in cell culture as well as animal models. In addition, in August 2014, the Company announced that it has restarted our anti-Ebola drug development program, in response to the current Ebola epidemic. The Company’s platform technology enables rapid development of drug candidates against novel infections. The Company believes that it will continue to expand its pipeline as available funds and opportunities permit.
	The Company is also working on scaling up production processes, and enabling c-GMP-compliant manufacture of its drug candidates in order to provide clinical supplies for the future human clinical trials of our drug candidates. Construction of the modern, multi-product, state-of-the-art nanomedicines manufacturing facility built for this purpose was completed in July, 2014. Cleaning and Validation, as well as custom equipment fit-outs are in progress at present. The facility was built by Inno-Haven, LLC, a special-purpose company established for this purpose. Inno-Haven is controlled and managed by Dr. Anil Diwan, the Company’s co-founder, President, and Chairman. Inno-haven purchased the building in 1 Controls Drive, Shelton, CT, in August 2011, with personal funds, and loans from family friends, at a time when NanoViricides was unable to support this critical endeavor. With the Company’s improved finances, the Company now intends to purchase this facility from Inno-Haven.

Restatement_of_Previously_Issu

Restatement of Previously Issued Financial Statements	3 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Accounting Changes and Error Corrections [Text Block]	Note 2- Restatement of Previously Issued Financial Statements
	In connection with the preparation of our unaudited financial statements for the quarter ended December 31, 2014, we determined that in preparing our audited financial statements for the year ended June 30, 2014, we inadvertently overlooked the anti-dilution provisions in certain warrants issued in connection with the company’s private placements of securities. Specifically, the warrants issued contained certain anti-dilution ratchet provisions that provided for an adjustment to the exercise price of the warrants if the company issued any stock equivalent securities at a lower price in the future while the option was still outstanding.  Adjustments to settlement amounts by future equity offerings or contractual terms of other equity-linked financial instruments issued in a subsequent period are not inputs to the fair value of a fixed-for-fixed opinion on equity shares. Accordingly, the warrants are not considered indexed to its own stock and thus must be accounted for as derivative liabilities which require initial measurement at fair value and adjustment to fair value in subsequent periods. The Company determined that the error caused a material understatement of its derivative liability for the year ended June 30, 2014. As a result of this error, we restated our audited financial statements for the year ended June 30, 2014 and are restating the unaudited financial statements for the three months ended September 30, 2014 and 2013 contained herein.
	For the year ended June 30, 2014 this restatement increased the Company’s derivative liability and decreased Additional Paid in Capital by $5,235,682, decreased Accumulated deficit by $504,858 and reduced the Company’s loss for the year ended June 30, 2014 by $504,858. The results of the restatement for the three months ended September 30, 2013 were reflected in the financial statements for the Year ended June 30, 2014.
	In connection with the preparation of our unaudited financial statements for the quarter ended December 31, 2014 we determined that in preparing our unaudited financial statements for the quarter ended September 30, 2014, we inadvertently did not recognize a single compound embedded derivative included with the issuer’s redemption rights in the Series C Convertible Debenture and the holders conversion right to receive coupon interest in common stock of the issuer. The Series C Convertible Debentures were issued on July 2, 2014. The Company has restated its financial statements for the three month period ended September 30, 2014 to recognize Discount on Series C Debentures of $3,031,125 arising from$1,152,297 relative fair value of the Company’s Series A Preferred shares issued as interest and the fair value of $1,879,428 of the embedded derivative which was recognized as an increase in to derivative liability. Additionally $115,490 of interest expense was recognized due to amortization of the Discount on Series C Convertible Debentures. This resulted in a net adjustment of the originally reported discount of $1,373,479.
	The combined impacts of all the above adjustments to the line items in our unaudited financial statements for the periods covered by this Form 10Q/A are provided in the tables below:
	Schedule A – September 30, 2014
	Nanoviricides, Inc.
	Balance Sheets
		September 30, 2014		Net Adjustment		September 30,2014
		(Unaudited)				(Unaudited)
		Original				Restated
	ASSETS
	CURRENT ASSETS:
	Cash and cash equivalents	$	41,120,652			$	41,120,652
	Prepaid expenses		59,099				59,099
	Prepaid expenses - related parties		424,402				424,402
	Other current assets		-				-
	Total Current Assets		41,604,153	-			41,604,153
	PROPERTY AND EQUIPMENT
	Property and equipment		7,299,254				7,299,254
	Accumulated depreciation		-1,291,318				-1,291,318
	Property and equipment, net		6,007,936				6,007,936
	TRADEMARK
	Trademark		458,954				458,954
	Accumulated amortization		-52,889				-52,889
	Trademark, net		406,065				406,065
	SECURITY DEPOSIT		1,000,000				1,000,000
	Total Assets	$	49,018,154			$	49,018,154
	LIABILITIES AND STOCKHOLDERS' EQUITY
	CURRENT LIABILITIES:
	Accounts payable	$	155,978			$	155,978
	Accounts payable – related parties		331,448				331,448
	Accrued expenses		265,463				265,463
	Total Current Liabilities		752,889				752,889
	Debentures payable - Series B Net of discount		4,195,296				4,195,296
	Derivative Liability - Series B Debentures		3,785,385				3,785,385
	Derivative Liability - Warrants		-	4,558,581			4,558,581
	Debentures Payable - Series C, Net of discount		3,457,244	-1,373,479			2,083,765
	Derivative Liability - Series C Debentures		-	1,453,122			1,453,122
	Total Long Term Liabilities		11,437,925	4,638,224			16,076,149
	Total Liabilities		12,190,814				16,829,038
	COMMITMENTS AND CONTINGENCIES
	STOCKHOLDERS' EQUITY:
	Series A Convertible Preferred stock, $0.001 par value, 4,000,000 shares designated, 3,387,795 and 3,193,079 shares issued and outstanding, respectively		3,389				3,389
	Series B Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 0, and 0 shares issued and outstanding, respectively		-				-
	Series C Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 0 and 0 shares issued and outstanding, respectively		-				-
	Common stock, $0.001 par value; 85,714,285 shares authorized; 56,535,135 and 54,620,993 shares issued and outstanding, respectively		56,535				56,535
	Additional paid-in capital		89,412,744	-6,233,849			83,178,895
	Accumulated deficit		-52,645,328	1,595,625			-51,049,703
	Total Stockholders' Equity		36,827,340	-4,638,224			32,189,116
	Total Liabilities and Stockholders' Equity	$	49,018,154			$	49,018,154
	Nanoviricides, Inc.
	Statements of Operations
	(Unaudited)
		For the Three Months				For the Three Months
		Ended				Ended
		September 30, 2014		Net Adjustments		30-Sep-14
		(Unaudited)				(Unaudited )
		Original				Restated
	OPERATING EXPENSES
	Research and development	$	811,107			$	811,107
	Refund credit research and development costs		-				-
	General and administrative		876,026				876,026
	Total operating expenses		1,687,133				1,687,133
LOSS FROM OPERATIONS		-1,687,133				-1,687,133
OTHER INCOME (EXPENSE):
Interest income, net		39,323				39,323
Interest expense		-245,000				-245,000
Discount on convertible debentures		-260,578	-12,640			-273,218
Beneficial conversion feature of convertible debentures		-				-
Change in fair market value of derivatives		1,914,318	1,103,407			3,017,725
Other income (expense), net		1,448,063	1,090,767			2,538,830
INCOME (LOSS) BEFORE INCOME TAXES		-239,070	1,090,767			851,697
INCOME TAX PROVISION		-				-
NET INCOME (LOSS)	$	-239,070	1,090,767		$	851,697
NET INCOME (LOSS) PER COMMON SHARE
- BASIC AND DILUTED:	$	-0.004			$	0.015
Weighted average common shares outstanding
- basic and diluted		55,576,200				55,576,200
Nanoviricides, Inc.
Statements of Cash Flows
(Unaudited)
	For the Three Months				Fot the Three Months
	Ended				Ended
	September 30, 2014		Net Adjustment		Septembr 30,2014
	Original				Restated
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	-239,070	1,090,767		$	851,697
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued for license
Series A Preferred shares issued as compensation		72,980				72,980
Common shares and warrants issued for services		38,250				38,250
Common shares issued for interest
Warrants granted to scientific advisory board		22,292				22,292
Amortization of deferred compensation
Depreciation		51,332				51,332
Amortization		2,193				2,193
Change in fair value of derivative liability		-1,914,318	-1,103,407			-3,017,725
Amortization of deferred financing expenses						-
Discount convertible debentures		260,578	12,640			273,218
Beneficial conversion feature of convertible debentures
Changes in operating assets and liabilities:
Prepaid expenses		48,990				48,990
Prepaid expenses - Related parties		284,819				284,819
Other current assets		150,000				150,000
Deferred expenses
Accounts payable - trade		-220,468				-220,468
Accounts payable - related parties		-427,228				-427,228
Accrued expenses		173,625				173,625
Accrued payroll to officers and related payroll tax expense
NET CASH USED IN OPERATING ACTIVITIES		-1,696,025	-			-1,696,025
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposit		-
Purchase of property and equipment		-562,512				-561,512
Purchase of trademark		-				-
NET CASH USED IN INVESTING ACTIVITIES		-562,512				-562,512
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debentures
Proceeds from issuance of Convertible Preferred Series B stock, net
Proceeds from issuance of Convertible Preferred Series C stock, net
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs
Proceeds from exercise of stock options
Proceeds from exercise of warrants		6,682,297				6,682,297
Collection of stock subscriptions received
NET CASH PROVIDED BY FINANCING ACTIVITIES		6,682,297				6,682,297
NET CHANGE IN CASH		4,423,760	-			4,693,131
Cash at beginning of period		36,696,892				36,696,892
Cash at end of period	$	41,120,652			$	41,120,652
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	$	-			$	-
Income tax paid	$	-			$	-
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common stock issued for services rendered	$	38,250				38,250.00
Common stock for interest
Preferred stock issued as compensation		72,980				72,980.00
Series A Preferred stock issued as discount on Debentures		1,645,606				1,645,606.00
Stock options issued to the officers as compensation
Stock warrants granted to scientific advisory board		22,292				22,292.00
Schedule B – September 30, 2013
Nanoviricides, Inc.
Balance Sheets
	September 30, 2013					September 30,2013
	(Unaudited)					(Unaudited)
	As Original Reported		Net Adjustment			As Restated
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	19,200,882	$			$	19,200,882
Prepaid expenses		805,145					805,145
Total Current Assets		20,006,027					20,006,027
PROPERTY AND EQUIPMENT
Property and equipment		3,779,636					3,779,636
Accumulated depreciation		-1,089,471					-1,089,471
Property and equipment, net		2,690,165					2,690,165
TRADEMARK
Trademark		458,954					458,954
Accumulated amortization		-44,114					-44,114
Trademark, net		414,840					414,840
SECURITY DEPOSIT		2,000,000					2,000,000
Total Assets	$	25,111,032				$	25,111,032
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$	408,058				$	408,058
Accounts payable – related parties		1,139,825					1,139,825
Accrued expenses		319,612					319,612
Total Current Liabilities		1,867,495					1,867,495
Debentures payable		3,603,554					3,603,554
Derivative liability - Debenture		7,888,736					7,888,736
Derivative liability - Warrants		-		3,443,717			3,443,717
Total Long Term Liabilities		11,492,290		3,443,717			14,936,007
Total Liabilities		13,359,785		3,443,717			16,803,502
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 2,990,000 shares designated, 2,990,000 shares issued and outstanding		2,990					2,990
Series B Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 0, and 0 shares issued and outstanding, respectively		-					-
Series C Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 0 and 0 shares issued and outstanding, respectively		-					-
Common stock, $0.001 par value; 85,714,285 shares authorized; 50,028,701 and 47,026,173 shares issued and outstanding, respectively		50,029					50,029
Additional paid-in capital		56,270,792		-3,154,975			53,115,817
Deficit accumulated during the development stage		-44,572,564		-288,742			-44,861,306
Total Stockholders' Equity		11,751,247		-3,443,717			8,307,530
Total Liabilities and Stockholders' Equity	$	25,111,032	$			$	25,111,032
Nanoviricides, Inc.
Statements of Operations
	For the Three Months				For the Three Months
	Ended				Ended
	September 30, 2013				September 30, 2013
	(Unaudited)				(Unaudited)
	As Original Reported		Net Adjustment		As Restated
OPERATING EXPENSES
Research and development	$	1,174,221			$	1,174,221
Refund credit research and development costs		-				-
General and administrative		714,561				714,561
Total operating expenses		1,888,782	-			1,888,782
LOSS FROM OPERATIONS		-1,888,782	-			-1,888,782
OTHER INCOME (EXPENSE):
Interest income, net		9,560				9,560
Interest expense		-120,986				-120,986
Discount on convertible debentures		-135,481				-135,481
Beneficial conversion feature of convertible debentures		-				-
Change in fair market value of derivatives		-4,137,091	-288,742			-4,425,833
Other income (expense), net		-4,383,998	-288,742			-4,672,740
LOSS BEFORE INCOME TAXES		-6,272,780	-288,742			-6,561,522
INCOME TAX PROVISION		-	-			-
NET LOSS	$	-6,272,780	-288,742		$	-6,561,522
NET LOSS PER COMMON SHARE
- BASIC AND DILUTED:	$	-0.13			$	-0.14
Weighted average common shares outstanding
- basic and diluted		47,672,029				47,672,029
Nanoviricides, Inc.
Statements of Cash Flows
	For the Three Months					For the Three Months
	Ended					Ended
	September 30, 2013					September 30, 2013
	(Unaudited)					(Unaudited)
	As Original Reported		Net Adjustment			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	-6,272,780	$	-288,742		$	-6,561,522
Adjustments to reconcile net loss to net cash used in operating activities
Common shares and warrants issued for services		32,250					32,250
Warrants granted to scientific advisory board		106,050					106,050
Depreciation		52,719					52,719
Amortization		2,193					2,193
Change in fair value of derivative liability		4,137,091		288,742			4,425,833
Discount convertible debentures		135,481					135,481
Changes in operating assets and liabilities:
Prepaid expenses		-206,765					-206,765
Accounts payable - trade		144,802					144,802
Accounts payable - related parties		429,258					429,258
Accrued expenses		115,253					115,253
NET CASH USED IN OPERATING ACTIVITIES		-1,324,448		-			-1,324,448
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposit		-1,000,000					-1,000,000
Purchase of property and equipment		-2,273,989					-2,273,989
NET CASH USED IN INVESTING ACTIVITIES		-3,273,989		-			-3,273,989
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs		9,690,450					9,690,450
Proceeds from exercise of warrants		185,624					185,624
NET CASH PROVIDED BY FINANCING ACTIVITIES		9,876,074					9,876,074
NET CHANGE IN CASH		5,277,637					5,277,637
Cash at beginning of period		13,923,245					13,923,245
Cash at end of period	$	19,200,882				$	19,200,882
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	$	-				$	-
Income tax paid	$	-				$	-
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common stock issued for services rendered	$	32,250				$	32,250
Stock warrants granted to scientific advisory board	$	106,050				$	106,050
Stock warrants granted to brokers	$	113,696				$	113,696

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 3 - Summary of Significant Accounting Policies
	Basis of Presentation – Interim Financial Information
	The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management,   considered necessary for a fair presentation of the results for the interim periods presented.  Interim results are not necessarily indicative of the results for the full year.  The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s form 10-K/A for the fiscal year ended June 30, 2014 filed with the SEC.
	For a summary of significant accounting policies (which have not changed from June 30, 2014), see the Company’s Annual Report on Form 10-K/A for the fiscal year ended June 30, 2014.
	Net Income (Loss) per Common Share
	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the	For the Fiscal
		Three Months	Year
		Ended	Ended
		September 30, 2014	September 30, 2013
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.35 per share expiring ten (10) years from the date of issuance	535,715	535,715
	Sub-total: stock options	535,715	535,715
	Warrants
	Warrants issued from June 15,2006 to October 1, 2007  to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	466,486
	Warrants issued from June 15, 2008 through May 15, 2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2015	211,429	211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015	65,714	65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016	68,571	68,571
	Warrants issued from August 16, 2012 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017	68,571	68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through September 30, 2014	2,810,071	2,910,071
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017	17,143	17,143
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018	58,910	58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017	17,143
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019	2,479,935
	Warrants issued on January 24, 2014 to investors with an exercise price of $5.25 per share expiring January 24, 2019	76,306
	Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018	17,143
	Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018	17148
	Warrants issued on August 15, 2014 to SAB for services with an exercise price of $5.02 per share expiring on August 15, 2018	17,148
	Sub-total: warrants	5,925,231	6,386,680
	Total potentially outstanding dilutive common shares	6,460,946	6,922,395
	In addition the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the Debentures is payable in restricted shares of the Company’s $0.001 par value common stock or in warrants, according to the terms of the Debenture.
	At September 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock into which these Debentures can be converted is 1,960,785 based upon the Selling price of the Company’s common stock on September 30, 2014 of $3.06. At September 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock arising from the payment of a portion of the future interest to be paid on the debentures in common shares or warrants is 1,142,858.
	The Company has also issued 3,387,795 of $0.001 par value Convertible Preferred A shares to investors and others. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. At September 30, 2014, the estimated number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into, is 11,857,283.
	Recently Issued Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
	The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
	The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	The company has limited operations and is considered to be in the development stage. The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage. The Company adopted this guidance from June 30, 2014
	In June 2014, the FASB issued the FASB Accounting Standards Update No. 2014-12 “Compensation—Stock Compensation (Topic 718) : Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).
	The amendments clarify the proper method of accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period.  The Update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition.  The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015.  Earlier adoption is permitted. The adoption of the ASU would not have a material effect on the accompanying financial statements.
	In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements— Going Concern (Subtopic 205-40) (Topic 718): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”).
	The Update provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes.
	This Update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. Earlier adoption is permitted.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Financial_Condition

Financial Condition	3 Months Ended
	Sep. 30, 2014
Financial Conditions Disclosure [Abstract]
Financial Conditions Disclosure [Text Block]	Note 4 - Financial Condition
	The Company’s financial statements for the interim period ended September 30, 2014 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business.  The Company has a deficit accumulated from inception.  In addition, the Company has not generated any revenues and no revenues are anticipated in the short-term.  Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs.  The Company has not yet commenced any product commercialization.  Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2014 the Company had cash and cash equivalents of $41,120,652. The Company has sufficient capital to continue its business, at least, through September 30, 2016, at the current rate of expenditure. The Company therefore would not be considered to have risks relative to its ability to continue as a going concern within the applicable guidelines.
	While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities.
	On July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 shall be calculated on a per diem basis from the Closing Date. The Company has the right, but not the obligation, to repay the Debenture prior to the Maturity Date (the “Redemption Payment”) in cash or, at the option of the Holder, a number of shares of the Company’s Common Stock. If the closing bid price of the Common Stock is in excess of $5.25 when the Company notifies the Holder it has elected to prepay the Debenture (the “Redemption Date”), the Company must redeem the Debenture by delivering to the Holder 951,381 shares of Common Stock and any unpaid coupon interest in lieu of a cash Redemption Payment. If the Holder elects to receive the Redemption Payment in cash, or if the closing bid price of the Common Stock is less than $5.25, the Company shall pay to the Holder a Redemption Payment in cash equal to the principal amount of the Debenture, plus any accrued coupon interest, and additional interest of 7% per annum for the period from the Closing Date to the Redemption Date. As additional interest on the Debenture, the Company shall issue 187,000 shares of its restricted Series A Preferred Stock (the “Series A”) to the Holder. Each shares of Series A votes at 9 votes per share. In addition, only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. The Offering was conducted directly by the Company without the use of a placement agent. Accordingly, no placement agent fees or other commissions were paid by the Company in connection with the Offering.
	On September 5, 2014, NanoViricides, Inc. (the “Company”) accepted notices to exercise old warrants (See Note 9, below.) for the purchase of an aggregate of 2,136,655 shares of the Company’s common stock at the exercise price of $3.50 per share for aggregate proceeds of $7,478,292.50. On July 17, 2014, the Company filed a registration statement on Form S-3 (the “Form S-3”) registering an aggregate of 3,071,986 shares of common stock underlying warrants previously issued by the Company in various private placement offerings between 2005 and September 2009 (the “Old Warrants”), as described more fully in the Form S-3 (the “Registered Warrants”). The Form S-3 was declared effective by the Securities and Exchange Commission on August 1, 2014. As of August 15, 2014, any Registered Warrants as specified above and not previously exercised have expired.
	As a result of the successful sale of the Company’s Common Shares, management believes that the Company has sufficient cash and cash equivalents to meet its budgeted expenditures through, at least, September 30, 2016 at current rate of expenditures.
	Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral nanomedicines.  The Company has not yet commenced any product commercialization.  The Company has incurred significant losses from operations since its inception, resulting in a an accumulated deficit of $(52,645,328) at September 30, 2014 and expects recurring losses from operations to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations.  There can be no assurance that the Company will achieve or maintain profitability in the future.  Despite the Company’s financings in 2014 and 2013 and a cash and cash equivalent balance of $41,120,652 at September 30, 2014, substantial additional financing will be required in future periods.  The Company may require additional capital to finance planned and currently unplanned capital costs, and additional staffing requirements during the next twenty four months.  The Company has, in the past, adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its Plan of Operations as necessary, if it is unable to raise such additional funds.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 5 - Related Party Transactions
	Related Parties
	Related parties with whom the Company had transactions are:
	Related Parties	Relationship
	Anil R. Diwan	Chairman, President, significant stockholder and director
	Eugene Seymour	CEO, Significant shareholder, Director
	TheraCour Pharma, Inc.	An entity owned and controlled by significant stockholder
	InnoHaven, LLC	An entity owned and controlled by significant stockholder
	Milton Boniuk, MD	Director and significant stockholder
	Fixed Assets
		September 30, 2014		June 30, 2014
	During the reporting period, InnoHaven, LLC, acquired fixed assets on behalf of the Company from third party vendors behalf of the Company at 1 Controls Drive, Shelton, Ct	$	-	$	4,500,000
	During the reporting Period, Thera Cour Pharma, Inc. acquired fixed assets on behalf of the Company from third party vendors	$	110,578	$	528,000
	Account Payable – Related Party
		September 30, 2014		June 30 , 2014
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies.. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc on the reporting date was	$	331,448	$	758,676
	Research and Development Costs Paid to Related Parties
		September		September 30,
		30, 2014		2013
	Development and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. As of September 30, 2014, pursuant to its license agreement, the Company has paid a security advance of $424,402 to and held by TheraCour Pharma, Inc. which is reflected in Prepaid Expenses. No royalties are due TheraCour from the Company’s inception through June 30, 2014.	$	769,185	$	924,125
	Long-Term Debentures Payable – Directors
		September 30, 2014		June 30, 2014
	On February 1, 2013, the Company raised $4M from a family investment office and a charitable foundation controlled by Dr. Milton Boniuk through the issuance of our Series B Debentures. The investors purchased unsecured convertible debentures with a 4-year term. The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal. The warrants are priced at $3.50 and will be valid for 3 years after issuance. The investors can convert the principal and any accrued interest into common stock at a fixed price of $3.50 per share. The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act.	$	4,000,000	$	4,000,000
	Repayments from inception to date		-		-
	Remaining balance		4,000,000		4,000,000
	Subsequent to the reporting period the Company on July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 has been accrued and will be paid over the remaining life of the Debenture commencing July 1, 2015.		5,000,000		5,000,000
	Repayments from inception to date		-		-
	Remaining balance		5,000,000		5,000,000
		$	9,000,000	$	9,000,000
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. (4) we will make royalty payments (calculated as a percentage of net sales of the licensed drugs) of 15% to TheraCour Pharma, Inc. (5) and agreed that TheraCour Pharma, Inc. retains the exclusive right to develop and manufacture the licensed drugs. TheraCour Pharma, Inc. agreed that it will manufacture the licensed drugs exclusively for NanoViricides, and unless such license is terminated, will not manufacture such product for its own sake or for others.

Concentrations

Concentrations	3 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	Note 6 - Concentrations
	Vendor purchase concentrations for September 30, 2014 and 2013 are as follows:
		Net Purchases						Accounts Payable
		For the three months ended September 30,						As of September  30,
		2014			2013			2014			2013
	TheraCour Pharma, Inc	769,185	45.6	%	924,126	48.9	%	331,448	68	%	1,139,825	73.6	%
	Kard Scientific, Inc.	-	0	%	247,660	13.1	%	123,570	25.4	%	246,963	16	%
	Total Purchases	1,687,133	100	%	1,888,782	100	%	487,426	100	%	1,547,883	100	%

Property_and_Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	N ote 7 - Property and Equipment
	Property and equipment, stated at cost, less accumulated depreciation consisted of the following:
		September 30,		June 30,
		2014		2014
	GMP Facility	$	3,551,713	$	3,099,780
	Office Equipment		30,048		30,048
	Furniture and Fixtures		1,400		1,400
	Lab Equipment		3,716,093		3,605,514
	Total Property and Equipment		7,299,254		6,736,742
	Less Accumulated Depreciation		-1,291,318		-1,239,986
	Property and Equipment, Net	$	6,007,936	$	5,496,756
	Depreciation expenses for the three months ended September 30, 2014 and 2013 were $51,332 and $52,719, respectively.

Trademark_and_Patents

Trademark and Patents	3 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 8 - Trademark and Patents
	Trademark and patents, stated at cost, less accumulated amortization consisted of the following:
		September 30,		June 30,
		2014		2014
	Trademarks and Patents	$	458,954	$	458,954
	Less Accumulated Amortization		-52,889		-50,696
	Trademarks and Patents, Net	$	406,065	$	408,258
	Amortization expense amounted to $2,193 and 2,193 for the three months ended September 30, 2014, and 2013, respectively.

Prepaid_Expenses

Prepaid Expenses	3 Months Ended
	Sep. 30, 2014
Prepaid Expenses [Abstract]
Prepaid Expenses Disclosure [Text Block]	Note 9 - Prepaid Expenses
	Prepaid Expenses are summarized as follows:
		September 30,		June 30,
		2014		2014
	TheraCour Pharma, Inc.	$	424,402	$	709,221
	Prepaid Others		59,099		108,089
		$	483,501	$	817,310

Equity_Transactions

Equity Transactions	3 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 10 - Equity Transactions
	On September 5, 2014, NanoViricides, Inc. (the “Company”) accepted notices to exercise old warrants for the purchase of an aggregate of 2,136,655 shares of the Company’s common stock at the exercise price of $3.50 per share for aggregate proceeds of $7,478,292.50. On July 17, 2014, the Company filed a registration statement on Form S-3 (the “Form S-3”) registering an aggregate of 3,071,986 shares of common stock underlying warrants previously issued by the Company in various private placement offerings between 2005 and September 2009, (“old warrants”) as described more fully in the Form S-3 (the “Registered Warrants”). The Form S-3 was declared effective by the Securities and Exchange Commission on August 1, 2014. As of August 15, 2014, any Registered Warrants as specified above and not previously exercised have expired.
	Unregistered Securities
	On July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”).
	On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 Shares of its Series A Convertible Preferred stock to Dr. Milton Boniuk as additional interest, pursuant to the terms of the Debenture.
	In connection with the preparation of our unaudited financial statements for the quarter ended December 31, 2014, we determined that in preparing our unaudited financial statements for the quarter ended September 30, 2014, we inadvertently did not recognize a single compound embedded derivative included with the issuer’s redemption rights in the Series C Convertible Debenture and the holders conversion right to receive coupon interest in common stock. See Note 2 to the financial statements.
	The Company first allocated the proceeds between the relative fair value of 187,000 of the Series A Convertible Preferred Stock and the Debenture and a debt discount is recorded to offset the amount of the proceeds allocated to the Preferred Stock, then the embedded derivative is bifurcated at fair value with the remaining balance allocated to the Debenture.
	There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a change of control of the Company. The Company, therefore, estimated the relative fair value of the Preferred A shares granted to various Employees on the date of grant. The Preferred Series A shares fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; ii) the value of the voting rights since the holder would lose the voting rights upon conversion. The conversion of the shares is triggered either by the Company or a Change of Control. The valuations of the Series A Preferred Stock as of 9/30/14 used the following inputs:
	a.	The common stock price (post-reverse split) was in the range $3.90 to $4.16;
	b.	54,614,930 to 56,450,000 shares outstanding and Series A Preferred shares with 2,572 (post–split 9/10/13) issued monthly ;
	c.	A 5.36% premium over the common shares for the voting preferences;
	d.	63,899,777 to 65,193,001 total voting shares and the monthly shares representing voting rights of 2.425% to 2.448% of the total;
	e.	The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 and a remaining restricted term of 2.59 to 2.42 years;
	f.	35.53% to 31.95% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 87.68% to 91.87% volatility, 0.47% to 0.58% risk free rate) applied to the converted common.
	The relative fair value of 187,000 shares of the Series A Preferred stock on issuance date was $1,152,297.
	The Company used a 3rd party consultant to develop a latticemodel that values the compound embedded derivatives of the Series C Convertible Debenture based on a probability weighted discounted cash flow model at issuance date and quarterly period ended September 30, 2014.
	The following assumptions were used for the valuation of the compound embedded derivative:
		⋅	The balance of the Series C Convertible Debenture as of issuance and 9/30/14 is $5,000,000;
		⋅	The underlying stock price was used as the fair value of the common stock; The pre–split stock price decreased from $0.8571 to $0.7771 which significantly increased the warrant value with the $1.00 exercise price (from out to in the money);
		⋅	The projected annual volatility was based on the Company historical volatility:
	1 year
	7/1/14 92%
	9/30/14 85%
	12/31/14 75%
		⋅	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%;
		⋅	The company would redeem the debentures projected initially at 0% of the time and increase monthly by 1.0% to a maximum of 5.0% (from alternative financing being available for a Redemption event to occur);
		⋅	The Holder would automatically convert the interest if the company was not in default and its shares value would equivalent to the cash value;
		⋅	The Holder would automatically convert the debenture at maturity if the registration was effective and the company was not in default.
		⋅	The Weighted Cost of Capital discount rate (based on the Market Value of the transaction at issuance) adjusted for changes in the risk free rate is 21.86%.
		⋅	Even through the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance.
	The fair value of the compound embedded derivatives of the Series C Convertible Debenture as of September 30, 2014 was $1,879,428.
	The Company recognized a charge of $3,031,125 as a discount of the Series C Debenture which will be amortized over the remaining life of the Debenture under the straight line method. For the three months ended September 30, 2014, the Company recognized $115,490 amortization of this discount as a charge to “Discount on convertible debentures”.
	In August, 2014, the Scientific Advisory Board (SAB) was granted warrants to purchase 17,148 shares of common stock at $5.02 per share expiring in August, 2018.  These warrants were valued at $22,292 and recorded as consulting expense.
	For the three months ended September 30, 2014, the Company’s Board of Directors authorized the issuance of 7,716 shares of its Series A Convertible Preferred stock for employee compensation. The Company recorded an expense of $72,980.
	For the three months ended September 30, 2014, the Company’s Board of Directors authorized the issuance of 2,059 shares of its common stock with a restrictive legend for consulting services. The Company recorded an expense of $27,000.
	For the three months ended September 30, 2014, the Company’s Board of Directors authorized the issuance of 2,856 shares of its common stock with a restrictive legend for Director services. The Company recorded an expense of $11,250.
	The Company estimated the relative fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		August 15,
		2014
	Expected life (year)			4
	Expected volatility			91.68	%
	Expected annual rate of quarterly dividends			0	%
	Risk-free rate(s)			1.2	%

Stock_Options_and_Warrants

Stock Options and Warrants	3 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 11 - Stock Options and Warrants
	Stock Options
	In September 2005, 142,857 stock options were granted to Eugene Seymour, our CEO under an employment agreement.  Of these options, 71,429 were vested immediately and are exercisable from September 2005 until September 2015, and the remaining  options vested annually on January 1, 2007 and 2008 in two  equal amounts.
	In September 2005, 285,715 stock options were granted to Anil Diwan, our Chairman and President under an employment agreement.  Of these options, 95,238 were vested immediately and are exercisable from September 2005 until September, 2015, and the remaining options vested annually on January 1, 2007 and January 1, 2008 in two equal amounts.
	In September 2005, 142,857 stock options were granted to Leo Ehrlich, our former CFO under an employment agreement. Of these options, 71,429 were vested immediately and are exercisable from September 2005 until September 2015, and the remaining options vest annually in two equal amounts.   On May 16, 2007, Leo Ehrlich resigned as the Company’s Chief Financial Officer. At time of his resignation 107,143 options were vested and are exercisable from September 2005 until September 2015. The remaining options were forfeited.
	The Company has accounted for these options granted to officers under the provisions of paragraph 718-10-30 of the FASB Accounting Standards Codification” and after giving effect to the 3.5 to 1 reverse split of September 9, 2013. Based on fair market value of these options, $7,044 was recognized as stock based compensation expense for the years ended June 30, 2009.  For the three months ended September 30, 2014 and 2013, the Company did not record any compensation expense related to these options.
	The following table presents the combined activity of stock options issued for the reporting periods ended September 30, 2014 as follows:
	Stock Options		Number of	Weighted		Weighted		Aggregate
			Shares	Average		Average		Intrinsic
				Exercise Price		Remaining		Value ($)
				per share ($)		Contractual
						Term (years)
	Outstanding at June 30, 2014		535,715	0.35		1.23		2,094,643
	Granted		-	-		-		-
	Exercised		-	-		-		-
	Expired		-	-		-		-
	Canceled		-	-		-		-
	Outstanding at September 30,2014		535,715	0.35		0.98		1,451,780
	As of September 30, 2014 there was no unrecognized compensation cost.
	Stock Warrants
	Stock Warrants	Number of		Weighted		Weighted			Aggregate
		Shares		Average		Average			Intrinsic Value
				Exercise		Remaining			($)
				Price		Contractual Term
				per share		(years)
				($)
	Outstanding at June 30, 2014		8,894,355		5.01		2.78			2,278,458
	Granted		17,148		4.18		3.88			-
	Exercised		1,926,656		-		-			-
	Expired		1,059,616		-		-			-
	Canceled		-		-		-			-
	Outstanding at September 30,2014		5,925,231		5.15		3.86			113,571
	Of the above warrants, 277,143 expire in fiscal year ending June 30, 2015; and 68,571 expire in fiscal year ended June 30, 2016; 68,571 expire in fiscal year ending June 30, 2017; 127,487 in fiscal year ending June 30,2018; 5,383,460 in fiscal year ending June 30, 2019.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 - Commitments and Contingencies
	Operating Lease
	The Company’s principal executive offices are located at 135 Wood Street, West Haven, Connecticut, and include approximately 7,000 square feet of office and laboratory space at a base monthly rent of $8,695. The term of lease expired on February 28, 2011 and is now on a month-by-month basis.
	Total rent expense at 135 Wood Street, West Haven, Connecticut amounted to $26,085 and $26,085 for the three months ended September 30, 2014 and 2013, respectively.
	On February 11, 2013, the Company entered into a binding Memorandum of Understanding (“MOU”) with Inno-Haven, LLC, a Connecticut Limited Liability Company (“Inno-Haven”), to lease for a four-year term a 18,000 square foot building located at 1 Controls Drive, Shelton, Connecticut (the “Leased Premises”), and for Inno-Haven to initiate renovation of the facility at the Company’s direction. The Company has filled out and completed such renovations as it determined were necessary for its specific use as a laboratory and GMP clean room drug manufacturing. Inno-Haven is controlled by Anil Diwan, the Company’s founder, President and Chairman and controlling shareholder of TheraCour Pharma, Inc., the Company’s principal shareholder (“TheraCour”). The MOU is subject to a definitive lease agreement (the “Lease Agreement”) to be executed upon final determination of the cost of the laboratory and GMP clean room, and which would contain definitive terms regarding rent, taxes, utilities, maintenance and other, similar items. Pursuant to the MOU, the Company has agreed to provide up to $2,000,000 in cash collateral for sums borrowed by Inno-Haven (collectively, the “Loans”) to complete the build-out and renovation of the Leased Premises for the benefit of the Company. The Company agreed to file a registration statement for shares of its restricted Common Stock, provided by TheraCour Pharma, Inc., as additional collateral for any or all of the Loans (the “Registrable Shares”). The Company shall file a registration statement within ninety (90) days of a closing of a Loan (a “Closing”) to cover such Registrable Shares and use its best efforts to have such registration statement declared effective no later than one hundred eighty (180) days following the Closing, and keep such registration statement effective until the termination of the respective collateral agreement, upon request to do so by Inno-Haven. The MOU further provides that, so long as there is no breach of the Lease Agreement by the Company, any distribution of the collateral in accordance with a Loan will first be made from the proceeds of life insurance policies (if applicable), then from the proceeds of the sale of the Registrable Shares, and then, should there be any balance still owing to the lender, from the cash collateral.
	On February 11, 2013, pursuant to the provisions of the MOU, the Company transferred $1,000,000 as cash collateral (the “Cash Collateral”) and agreed to register a number of shares of the Company’s Common Stock, which shares were provided by TheraCour Pharma, Inc., equal to $1,000,000 (the “Collateral Shares”) as collateral pursuant to a Loan and Security Agreement entered into between Inno-Haven and a non-affiliated lender (the “Loan Agreement”) for a loan in the principal amount of $2,000,000. On September 17, 2013, The Company transferred the remaining $1,000,000 cash collateral to Inno-Haven. The value of the Collateral Shares shall be determined every three months and, in the event that the current number of shares of the Common Stock is less than $1,000,000, Inno-Haven may deposit, and the Company shall register, additional shares to equal the aforesaid $1,000,000. Alternatively, Inno-Haven may deposit cash equal to the difference between $1,000,000 and the value of the Collateral Shares. Moreover, Inno-Haven is required to obtain a life insurance policy to insure the life of Dr. Diwan in the amount of $2,000,000. If Dr. Diwan dies during the term of the Loan Agreement, the lender shall have the option to demand payment of the balance of the loan, but, shall be repaid first from the proceeds of any life insurance policy (if applicable), then from the proceeds of the sale of the Collateral Shares, and then, should there be any balance still owing to the lender, from the Cash Collateral. As of September 30, 2014, the Company has utilized approximately $4.5 million for specific fixtures and improvements it required for the new laboratory and cGMP facilities.
	No lease agreement has been perfected with Inno-Haven to date. The Company engaged external consultants to help determine whether to lease this facility or to purchase it outright from Inno-Haven. Subsequently, the Company’s Board of Directors has authorized the acquisition of 1 Controls Drive from Inno-Haven in an amount equal to its costs in acquiring and fitting out 1 Controls Drive on the Company’s behalf.
	Total rent expense paid to Inno-Haven during this period amounted to $-0- for the Three months ended September 30, 2014 and $-0- since February 11, 2013.
	Legal Proceedings
	On or about January 18, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-654437-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”).  The Complaint seeks to compel inspection of the Company’s books and records.  On or about February 14, 2012 we filed a Motion to Dismiss the Complaint for failure to state a claim upon which relief can be granted.  The Complaint further seeks unspecified “injunctive relief” in furtherance of the demand for inspection to which it is not entitled.  The Complaint by a holder of less than 1 percent of the common stock of the Company seeks to, inter alia, inspect documents and records of the company to which it is not entitled and in a form and manner the Company argues is not authorized by statute.  Management believes that this lawsuit has no merit or basis and intends to vigorously defend it.  Monetary damages have not been claimed and as a result no accrual has been made in relation to this litigation. On April 9, 2012, the Court dismissed the Complaint for failure to state a Claim for which relief could be granted.
	On or about April 13, 2012, the Nevada Agency and Transfer Company, as agent for service of process for the Company in Nevada, was served with a Summons and Complaint in the case entitled Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc. (Case No. A-12-659535-B) answerable in the Eighth Judicial District Court of the State of Nevada – Clark County (“Court”). The Complaint seeks to compel inspection of the Company’s books and records. On or about May 2, 2012, the Company filed a Demand for Security of Costs. Upon filing of the Demand, proceedings relative to the Company are stayed pending posting of the demanded security (or plaintiff engages in motion practice about the Demand). The Company may seek dismissal of the complaint if plaintiff has not posted the demanded security (or engaged the court). The Complaint further seeks unspecified “injunctive relief” in furtherance of the demand for inspection to which the Company believes it is not entitled. The Complaint, by a holder of less than 1 percent of the common stock of the Company, seeks to, inter alia, inspect documents and records of the company to which it is not entitled and in a form and manner the Company argues is not authorized by statute. On or about July 18, 2012, the Plaintiff moved to amend its answer. On or about August 8, 2012, we filed our opposition to Plaintiff’s Motion to Amend and a Motion to Dismiss the Complaint for failure to state a claim upon which relief can be granted. On or about September 13, 2012 the court granted the Plaintiff’s Motion to Amend. On or about September 17, 2012 the Plaintiff served its “Second Amended Shareholder Derivative Complaint” upon our Counsel in Nevada. As in the prior two complaints that this Plaintiff has filed in this action, the Second Amended Complaint sought to compel inspection of the Company’s books and records, sought injunctive relief, an accounting and alleges breach of Fiduciary by Dr. Seymour and Dr. Diwan. On or about October 11, 2012, we filed a Motion to Dismiss the Second Amended Complaint for failure to state a claim upon which relief can be granted. On or about December 4, 2012, the Court granted the Company’s Motion to Dismiss with respect to Dr. Seymour and Dr. Diwan and ordered the case dismissed as to all claims but the Plaintiff’s request to compel documents required to be maintained by the Company’s registered agent in Nevada pursuant to NRS 78.105. On or about December 26, 2012, the Company provided the Plaintiff with each of the documents to which it is entitled. Management believes that the Plaintiff does not have a legal or good faith basis for inspection or copying of its shareholder’s list and intends to vigorously defend the production thereof. In May, 2013, the Plaintiff filed a motion for permission to file a third amended complaint. The Company subsequently filed a motion to dismiss and for Summary Judgment. The Court denied the Motion to Dismiss and for Summary Judgment and ordered the Plaintiff to file its Third Amended Complaint. On or about July 15, 2013 the Company Petitioned the Nevada Supreme Court for a Writ of Prohibition or Mandamus reversing the trial Court’s denial of Summary Judgment. Thereafter, on or about September 20, 2013, the Nevada Supreme Court denied the Company’s Writ Petition. The Company filed its answer to the Third Amended Complaint, which contains only one cause of action which is identical to the sole cause of action which was not dismissed from the Second Amended Complaint. Specifically, the Third Amended Complaint seeks only to compel production of books and records required to be maintained by the Company’s Registered Agent pursuant to NRS 78.105 Management believes that the Company’s registered Agent has provided the Plaintiff with all documents to which it is entitled pursuant to NRS 78.105 and that this lawsuit has no merit or basis. The Company has vigorously defended this lawsuit. Following cross-motions for summary judgment and certain discovery as limited by the court, the parties engaged in a settlement conference in March 2014, at which time an agreement was reached resolving the parties’ disputes in this matter. Pursuant to the Settlement Agreement, the Company deposited $150,000 with its attorney to be released to reimburse the Plaintiff for a portion of its litigation expenses. However, disagreements later arose regarding the negotiated resolution, precipitating, among other things, the Company’s application for court intervention and repeated status hearings. Final settlement documents were fully exchanged on September 11, 2014. Upon the Plaintiff’s compliance with the terms of the Settlement Agreement, the Company authorized counsel to release the reimbursement amount to the Plaintiff. An order dismissing the foregoing lawsuit was entered on September 16, 2014.
	On or about July 15, 2013 the same Plaintiff that had filed the repetitive complaints in the Nevada action as set forth in the preceding paragraphs (Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and NanoViricides, Inc.) filed a Shareholder Derivative complaint with the United States District Court for the District of Colorado.  The Plaintiff asserted the action is a shareholder derivative action and the Company is solely a nominal defendant.  The Company maintains that it, as well as the individual defendants, Messrs. Seymour and Diwan, have not been served in the action. However, a default was filed against the Company, which has been vacated. The Complaint alleges that the Company has failed to deliver information requested by the Plaintiff, the identical information the Plaintiff is seeking inspection of in the Nevada action, and that the individual defendants, Messrs. Seymour and Diwan, breached their fiduciary duties to the Company and caused it financial harm.  The Plaintiff demanded an order to inspect the Company’s records, an order revoking Messrs. Diwan and Seymour from the Board of Directors, equitable relief, and consequential and punitive damages.  The Company believes these claims had no merit and defended this action vigorously. The Company moved the District Court to dismiss the action in its entirety. No facts have been submitted to support the claimed vague consequential and punitive damages. Management has determined that such claims are specious and not relevant to the Company and no accrual has been made in relation to this litigation. The action was settled and dismissed with prejudice pursuant to the Settlement Agreement in the above referenced Nevada action. Similarly, upon the Plaintiff’s compliance with the terms of the Settlement Agreement, the Company authorized counsel to release the reimbursement amount to the Plaintiff. An order dismissing the foregoing lawsuit was entered on September 16, 2014.
	There are no other legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company.

Subsequent_Events

Subsequent Events	3 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 13 - Subsequent Events
	Management has evaluated all events that occurred after the balance sheet date through the date when these financial statements were issued to determine if they must be reported. The Management of the Company has determined that the following reportable subsequent event is required to be disclosed:
	On October 31, 2014, the Company filed a Registration Statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”).  The Registration Statement is a “universal” shelf registration statement for the registration of up to $50 million of our common stock, preferred stock, warrants, debt securities and units comprised of any or all of such securities.  If and when the Registration Statement is declared effective, the Company will be able tooffer and sell, from time to time, up to $50 million of securities, including shares of the Company’s common stock and preferred stock, debt securities, warrants, and units, the terms of which will be described in prospectus supplements filed with the Commission, as applicable.  Such securities may not be sold, nor may offers to buy be accepted, until the Registration Statement is declared effective by the Commission

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – Interim Financial Information
	The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management,   considered necessary for a fair presentation of the results for the interim periods presented.  Interim results are not necessarily indicative of the results for the full year.  The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our company’s audited financial statements and related notes included in our company’s form 10-K/A for the fiscal year ended June 30, 2014 filed with the SEC.
	For a summary of significant accounting policies (which have not changed from June 30, 2014), see the Company’s Annual Report on Form 10-K/A for the fiscal year ended June 30, 2014.
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) per Common Share
	Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the	For the Fiscal
		Three Months	Year
		Ended	Ended
		September 30, 2014	September 30, 2013
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.35 per share expiring ten (10) years from the date of issuance	535,715	535,715
	Sub-total: stock options	535,715	535,715
	Warrants
	Warrants issued from June 15,2006 to October 1, 2007  to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	466,486
	Warrants issued from June 15, 2008 through May 15, 2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2015	211,429	211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015	65,714	65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016	68,571	68,571
	Warrants issued from August 16, 2012 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017	68,571	68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through September 30, 2014	2,810,071	2,910,071
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017	17,143	17,143
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018	58,910	58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017	17,143
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019	2,479,935
	Warrants issued on January 24, 2014 to investors with an exercise price of $5.25 per share expiring January 24, 2019	76,306
	Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018	17,143
	Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018	17148
	Warrants issued on August 15, 2014 to SAB for services with an exercise price of $5.02 per share expiring on August 15, 2018	17,148
	Sub-total: warrants	5,925,231	6,386,680
	Total potentially outstanding dilutive common shares	6,460,946	6,922,395
	In addition the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the Debentures is payable in restricted shares of the Company’s $0.001 par value common stock or in warrants, according to the terms of the Debenture.
	At September 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock into which these Debentures can be converted is 1,960,785 based upon the Selling price of the Company’s common stock on September 30, 2014 of $3.06. At September 30, 2014 the estimated number of potentially dilutive shares of the Company’s common stock arising from the payment of a portion of the future interest to be paid on the debentures in common shares or warrants is 1,142,858.
	The Company has also issued 3,387,795 of $0.001 par value Convertible Preferred A shares to investors and others. Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. At September 30, 2014, the estimated number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into, is 11,857,283.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
	The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
	The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	The company has limited operations and is considered to be in the development stage. The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage. The Company adopted this guidance from June 30, 2014
	In June 2014, the FASB issued the FASB Accounting Standards Update No. 2014-12 “Compensation—Stock Compensation (Topic 718) : Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).
	The amendments clarify the proper method of accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period.  The Update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition.  The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015.  Earlier adoption is permitted. The adoption of the ASU would not have a material effect on the accompanying financial statements.
	In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements— Going Concern (Subtopic 205-40) (Topic 718): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”).
	The Update provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes.
	This Update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures.
	The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. Earlier adoption is permitted.
	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Restatement_of_Previously_Issu1

Restatement of Previously Issued Financial Statements (Tables)	3 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	Balance Sheets
		September 30, 2014		Net Adjustment		September 30,2014
		(Unaudited)				(Unaudited)
		Original				Restated
	ASSETS
	CURRENT ASSETS:
	Cash and cash equivalents	$	41,120,652			$	41,120,652
	Prepaid expenses		59,099				59,099
	Prepaid expenses - related parties		424,402				424,402
	Other current assets		-				-
	Total Current Assets		41,604,153	-			41,604,153
	PROPERTY AND EQUIPMENT
	Property and equipment		7,299,254				7,299,254
	Accumulated depreciation		-1,291,318				-1,291,318
	Property and equipment, net		6,007,936				6,007,936
	TRADEMARK
	Trademark		458,954				458,954
	Accumulated amortization		-52,889				-52,889
	Trademark, net		406,065				406,065
	SECURITY DEPOSIT		1,000,000				1,000,000
	Total Assets	$	49,018,154			$	49,018,154
	LIABILITIES AND STOCKHOLDERS' EQUITY
	CURRENT LIABILITIES:
	Accounts payable	$	155,978			$	155,978
	Accounts payable – related parties		331,448				331,448
	Accrued expenses		265,463				265,463
	Total Current Liabilities		752,889				752,889
	Debentures payable - Series B Net of discount		4,195,296				4,195,296
	Derivative Liability - Series B Debentures		3,785,385				3,785,385
	Derivative Liability - Warrants		-	4,558,581			4,558,581
	Debentures Payable - Series C, Net of discount		3,457,244	-1,373,479			2,083,765
	Derivative Liability - Series C Debentures		-	1,453,122			1,453,122
	Total Long Term Liabilities		11,437,925	4,638,224			16,076,149
	Total Liabilities		12,190,814				16,829,038
	COMMITMENTS AND CONTINGENCIES
	STOCKHOLDERS' EQUITY:
	Series A Convertible Preferred stock, $0.001 par value, 4,000,000 shares designated, 3,387,795 and 3,193,079 shares issued and outstanding, respectively		3,389				3,389
	Series B Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 0, and 0 shares issued and outstanding, respectively		-				-
	Series C Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 0 and 0 shares issued and outstanding, respectively		-				-
	Common stock, $0.001 par value; 85,714,285 shares authorized; 56,535,135 and 54,620,993 shares issued and outstanding, respectively		56,535				56,535
	Additional paid-in capital		89,412,744	-6,233,849			83,178,895
	Accumulated deficit		-52,645,328	1,595,625			-51,049,703
	Total Stockholders' Equity		36,827,340	-4,638,224			32,189,116
	Total Liabilities and Stockholders' Equity	$	49,018,154			$	49,018,154
	Balance Sheets
		September 30, 2013					September 30,2013
		(Unaudited)					(Unaudited)
		As Original Reported		Net Adjustment			As Restated
	ASSETS
	CURRENT ASSETS:
	Cash and cash equivalents	$	19,200,882	$			$	19,200,882
	Prepaid expenses		805,145					805,145
	Total Current Assets		20,006,027					20,006,027
	PROPERTY AND EQUIPMENT
	Property and equipment		3,779,636					3,779,636
	Accumulated depreciation		-1,089,471					-1,089,471
	Property and equipment, net		2,690,165					2,690,165
	TRADEMARK
	Trademark		458,954					458,954
	Accumulated amortization		-44,114					-44,114
	Trademark, net		414,840					414,840
	SECURITY DEPOSIT		2,000,000					2,000,000
	Total Assets	$	25,111,032				$	25,111,032
	LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$	408,058				$	408,058
Accounts payable – related parties		1,139,825					1,139,825
Accrued expenses		319,612					319,612
Total Current Liabilities		1,867,495					1,867,495
Debentures payable		3,603,554					3,603,554
Derivative liability - Debenture		7,888,736					7,888,736
Derivative liability - Warrants		-		3,443,717			3,443,717
Total Long Term Liabilities		11,492,290		3,443,717			14,936,007
Total Liabilities		13,359,785		3,443,717			16,803,502
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 2,990,000 shares designated, 2,990,000 shares issued and outstanding		2,990					2,990
Series B Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 0, and 0 shares issued and outstanding, respectively		-					-
Series C Convertible Preferred stock, $0.001 par value, 10,000,000 shares designated, 0 and 0 shares issued and outstanding, respectively		-					-
Common stock, $0.001 par value; 85,714,285 shares authorized; 50,028,701 and 47,026,173 shares issued and outstanding, respectively		50,029					50,029
Additional paid-in capital		56,270,792		-3,154,975			53,115,817
Deficit accumulated during the development stage		-44,572,564		-288,742			-44,861,306
Total Stockholders' Equity		11,751,247		-3,443,717			8,307,530
Total Liabilities and Stockholders' Equity	$	25,111,032	$			$	25,111,032
Statements of Operations
(Unaudited)
	For the Three Months				For the Three Months
	Ended				Ended
	September 30, 2014		Net Adjustments		30-Sep-14
	(Unaudited)				(Unaudited )
	Original				Restated
OPERATING EXPENSES
Research and development	$	811,107			$	811,107
Refund credit research and development costs		-				-
General and administrative		876,026				876,026
Total operating expenses		1,687,133				1,687,133
LOSS FROM OPERATIONS		-1,687,133				-1,687,133
OTHER INCOME (EXPENSE):
Interest income, net		39,323				39,323
Interest expense		-245,000				-245,000
Discount on convertible debentures		-260,578	-12,640			-273,218
Beneficial conversion feature of convertible debentures		-				-
Change in fair market value of derivatives		1,914,318	1,103,407			3,017,725
Other income (expense), net		1,448,063	1,090,767			2,538,830
INCOME (LOSS) BEFORE INCOME TAXES		-239,070	1,090,767			851,697
INCOME TAX PROVISION		-				-
NET INCOME (LOSS)	$	-239,070	1,090,767		$	851,697
NET INCOME (LOSS) PER COMMON SHARE
- BASIC AND DILUTED:	$	-0.004			$	0.015
Weighted average common shares outstanding
- basic and diluted		55,576,200				55,576,200
Statements of Operations
	For the Three Months				For the Three Months
	Ended				Ended
	September 30, 2013				September 30, 2013
	(Unaudited)				(Unaudited)
	As Original Reported		Net Adjustment		As Restated
OPERATING EXPENSES
Research and development	$	1,174,221			$	1,174,221
Refund credit research and development costs		-				-
General and administrative		714,561				714,561
Total operating expenses		1,888,782	-			1,888,782
LOSS FROM OPERATIONS		-1,888,782	-			-1,888,782
OTHER INCOME (EXPENSE):
Interest income, net		9,560				9,560
Interest expense		-120,986				-120,986
Discount on convertible debentures		-135,481				-135,481
Beneficial conversion feature of convertible debentures		-				-
Change in fair market value of derivatives		-4,137,091	-288,742			-4,425,833
Other income (expense), net		-4,383,998	-288,742			-4,672,740
LOSS BEFORE INCOME TAXES		-6,272,780	-288,742			-6,561,522
INCOME TAX PROVISION		-	-			-
NET LOSS	$	-6,272,780	-288,742		$	-6,561,522
NET LOSS PER COMMON SHARE
- BASIC AND DILUTED:	$	-0.13			$	-0.14
Weighted average common shares outstanding
- basic and diluted		47,672,029				47,672,029
Statements of Cash Flows
(Unaudited)
	For the Three Months				Fot the Three Months
	Ended				Ended
	September 30, 2014		Net Adjustment		Septembr 30,2014
	Original				Restated
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	-239,070	1,090,767		$	851,697
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued for license
Series A Preferred shares issued as compensation		72,980				72,980
Common shares and warrants issued for services		38,250				38,250
Common shares issued for interest
Warrants granted to scientific advisory board		22,292				22,292
Amortization of deferred compensation
Depreciation		51,332				51,332
Amortization		2,193				2,193
Change in fair value of derivative liability		-1,914,318	-1,103,407			-3,017,725
Amortization of deferred financing expenses						-
Discount convertible debentures		260,578	12,640			273,218
Beneficial conversion feature of convertible debentures
Changes in operating assets and liabilities:
Prepaid expenses		48,990				48,990
Prepaid expenses - Related parties		284,819				284,819
Other current assets		150,000				150,000
Deferred expenses
Accounts payable - trade		-220,468				-220,468
Accounts payable - related parties		-427,228				-427,228
Accrued expenses		173,625				173,625
Accrued payroll to officers and related payroll tax expense
NET CASH USED IN OPERATING ACTIVITIES		-1,696,025	-			-1,696,025
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposit		-
Purchase of property and equipment		-562,512				-561,512
Purchase of trademark		-				-
NET CASH USED IN INVESTING ACTIVITIES		-562,512				-562,512
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debentures
Proceeds from issuance of Convertible Preferred Series B stock, net
Proceeds from issuance of Convertible Preferred Series C stock, net
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs
Proceeds from exercise of stock options
Proceeds from exercise of warrants		6,682,297				6,682,297
Collection of stock subscriptions received
NET CASH PROVIDED BY FINANCING ACTIVITIES		6,682,297				6,682,297
NET CHANGE IN CASH		4,423,760	-			4,693,131
Cash at beginning of period		36,696,892				36,696,892
Cash at end of period	$	41,120,652			$	41,120,652
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	$	-			$	-
Income tax paid	$	-			$	-
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common stock issued for services rendered	$	38,250				38,250.00
Common stock for interest
Preferred stock issued as compensation		72,980				72,980.00
Series A Preferred stock issued as discount on Debentures		1,645,606				1,645,606.00
Stock options issued to the officers as compensation
Stock warrants granted to scientific advisory board		22,292				22,292.00
Statements of Cash Flows
	For the Three Months					For the Three Months
	Ended					Ended
	September 30, 2013					September 30, 2013
	(Unaudited)					(Unaudited)
	As Original Reported		Net Adjustment			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	-6,272,780	$	-288,742		$	-6,561,522
Adjustments to reconcile net loss to net cash used in operating activities
Common shares and warrants issued for services		32,250					32,250
Warrants granted to scientific advisory board		106,050					106,050
Depreciation		52,719					52,719
Amortization		2,193					2,193
Change in fair value of derivative liability		4,137,091		288,742			4,425,833
Discount convertible debentures		135,481					135,481
Changes in operating assets and liabilities:
Prepaid expenses		-206,765					-206,765
Accounts payable - trade		144,802					144,802
Accounts payable - related parties		429,258					429,258
Accrued expenses		115,253					115,253
NET CASH USED IN OPERATING ACTIVITIES		-1,324,448		-			-1,324,448
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposit		-1,000,000					-1,000,000
Purchase of property and equipment		-2,273,989					-2,273,989
NET CASH USED IN INVESTING ACTIVITIES		-3,273,989		-			-3,273,989
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs		9,690,450					9,690,450
Proceeds from exercise of warrants		185,624					185,624
NET CASH PROVIDED BY FINANCING ACTIVITIES		9,876,074					9,876,074
NET CHANGE IN CASH		5,277,637					5,277,637
Cash at beginning of period		13,923,245					13,923,245
Cash at end of period	$	19,200,882				$	19,200,882
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	$	-				$	-
Income tax paid	$	-				$	-
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common stock issued for services rendered	$	32,250				$	32,250
Stock warrants granted to scientific advisory board	$	106,050				$	106,050
Stock warrants granted to brokers	$	113,696				$	113,696

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net income (loss) per common share calculation as they were anti-dilutive:
		Potentially Outstanding Dilutive Common Shares
		For the	For the Fiscal
		Three Months	Year
		Ended	Ended
		September 30, 2014	September 30, 2013
	Stock options
	Stock options issued on September 23, 2005 to the founders of the Company upon formation with an exercise price of $0.35 per share expiring ten (10) years from the date of issuance	535,715	535,715
	Sub-total: stock options	535,715	535,715
	Warrants
	Warrants issued from June 15,2006 to October 1, 2007  to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	513,143
	Warrants issued on August 22, 2008 to investors in connection with the Company’s equity financing with an exercise price of $3.50 per share expiring August 15, 2014	-	466,486
	Warrants issued from June 15, 2008 through May 15, 2010 to SAB for services with an exercise price from $2.45 to $9.38 per share expiring February 28, 2015	211,429	211,429
	Warrants issued on June 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	568,771
	Warrants issued on September 30, 2009 to investors with an exercise price of $3.50 per share expiring August 15, 2014	-	1,437,871
	Warrants issued from August 16, 2010 to May 15, 2011 to SAB for services with an exercise price ranging from $5.15 to $6.34 per share expiring fiscal year ending June 30, 2015	65,714	65,714
	Warrants issued from August 16, 2011 to May 15, 2012 to SAB for services with an exercise price ranging from $2.80 to $4.94 per share expiring fiscal year ending June 30, 2016	68,571	68,571
	Warrants issued from August 16, 2012 to September 30, 2013 to SAB for services with an exercise price of $5.17 per share expiring fiscal year ending June 30, 2017	68,571	68,571
	Warrants issued on September 10, 2013 to investors with an exercise price of $5.25 per share expiring September 10, 2018 less Warrants exercised through September 30, 2014	2,810,071	2,910,071
	Warrants issued on August 15, 2013 to SAB for services with an exercise price of $5.17 per share expiring on August 15, 2017	17,143	17,143
	Warrants issued on September 10, 2013 to Placement Agents as commissions with an exercise price of $5.25 per share expiring September 10, 2018	58,910	58,910
	Warrants issued on November 15, 2013 to SAB for services with an exercise price of $6.56 per share expiring on November 15, 2017	17,143
	Warrants issued on January 24, 2014 to investors with an exercise price of $6.05 per share expiring January 24, 2019	2,479,935
	Warrants issued on January 24, 2014 to investors with an exercise price of $5.25 per share expiring January 24, 2019	76,306
	Warrants issued on February 14, 2014 to SAB for services with an exercise price of $3.98 per share expiring on February 14, 2018	17,143
	Warrants issued on May 15, 2014 to SAB for services with an exercise price of $4.11 per share expiring on May 15, 2018	17148
	Warrants issued on August 15, 2014 to SAB for services with an exercise price of $5.02 per share expiring on August 15, 2018	17,148
	Sub-total: warrants	5,925,231	6,386,680
	Total potentially outstanding dilutive common shares	6,460,946	6,922,395

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	3 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Fixed Assets
		September 30, 2014		June 30, 2014
	During the reporting period, InnoHaven, LLC, acquired fixed assets on behalf of the Company from third party vendors behalf of the Company at 1 Controls Drive, Shelton, Ct	$	-	$	4,500,000
	During the reporting Period, Thera Cour Pharma, Inc. acquired fixed assets on behalf of the Company from third party vendors	$	110,578	$	528,000
	Account Payable – Related Party
		September 30, 2014		June 30 , 2014
	Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies.. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc on the reporting date was	$	331,448	$	758,676
	Research and Development Costs Paid to Related Parties
		September		September 30,
		30, 2014		2013
	Development and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. As of September 30, 2014, pursuant to its license agreement, the Company has paid a security advance of $424,402 to and held by TheraCour Pharma, Inc. which is reflected in Prepaid Expenses. No royalties are due TheraCour from the Company’s inception through June 30, 2014.	$	769,185	$	924,125
	Long-Term Debentures Payable – Directors
		September 30, 2014		June 30, 2014
	On February 1, 2013, the Company raised $4M from a family investment office and a charitable foundation controlled by Dr. Milton Boniuk through the issuance of our Series B Debentures. The investors purchased unsecured convertible debentures with a 4-year term. The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal. The warrants are priced at $3.50 and will be valid for 3 years after issuance. The investors can convert the principal and any accrued interest into common stock at a fixed price of $3.50 per share. The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act.	$	4,000,000	$	4,000,000
	Repayments from inception to date		-		-
	Remaining balance		4,000,000		4,000,000
	Subsequent to the reporting period the Company on July 2, 2014, (the “Closing Date”), the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “Debenture”) from Dr. Milton Boniuk, a member of the Company’s Board of Directors (the “Holder”). The $5,000,000 funding of the Debenture had been received by the Company prior to June 30, 2014, the year end reporting period and the Company has reported the said Debenture in these financial statements under long term liabilities. The Debenture is due on June 30, 2018 (the “Maturity Date”) and is convertible, at the sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at the conversion price of $5.25 per share of Common Stock. The Debenture bears interest at the coupon rate of ten percent (10%) per annum, computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December 31 of each calendar year until the Maturity Date. Interest for the first quarter ending September 30, 2014 has been accrued and will be paid over the remaining life of the Debenture commencing July 1, 2015.		5,000,000		5,000,000
	Repayments from inception to date		-		-
	Remaining balance		5,000,000		5,000,000
		$	9,000,000	$	9,000,000

Concentrations_Tables

Concentrations (Tables)	3 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Vendor purchase concentrations for September 30, 2014 and 2013 are as follows:
		Net Purchases						Accounts Payable
		For the three months ended September 30,						As of September  30,
		2014			2013			2014			2013
	TheraCour Pharma, Inc	769,185	45.6	%	924,126	48.9	%	331,448	68	%	1,139,825	73.6	%
	Kard Scientific, Inc.	-	0	%	247,660	13.1	%	123,570	25.4	%	246,963	16	%
	Total Purchases	1,687,133	100	%	1,888,782	100	%	487,426	100	%	1,547,883	100	%

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following:
		September 30,		June 30,
		2014		2014
	GMP Facility	$	3,551,713	$	3,099,780
	Office Equipment		30,048		30,048
	Furniture and Fixtures		1,400		1,400
	Lab Equipment		3,716,093		3,605,514
	Total Property and Equipment		7,299,254		6,736,742
	Less Accumulated Depreciation		-1,291,318		-1,239,986
	Property and Equipment, Net	$	6,007,936	$	5,496,756

Trademark_and_Patents_Tables

Trademark and Patents (Tables)	3 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents, stated at cost, less accumulated amortization consisted of the following:
		September 30,		June 30,
		2014		2014
	Trademarks and Patents	$	458,954	$	458,954
	Less Accumulated Amortization		-52,889		-50,696
	Trademarks and Patents, Net	$	406,065	$	408,258

Prepaid_Expenses_Tables

Prepaid Expenses (Tables)	3 Months Ended
	Sep. 30, 2014
Prepaid Expenses [Abstract]
Schedule Of Prepaid Expenses [Table Text Block]	Prepaid Expenses are summarized as follows:
		September 30,		June 30,
		2014		2014
	TheraCour Pharma, Inc.	$	424,402	$	709,221
	Prepaid Others		59,099		108,089
		$	483,501	$	817,310

Equity_Transactions_Tables

Equity Transactions (Tables)	3 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	The Company estimated the relative fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions:
		August 15,
		2014
	Expected life (year)		4
	Expected volatility		91.68	%
	Expected annual rate of quarterly dividends		0	%
	Risk-free rate(s)		1.2	%

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	3 Months Ended
	Sep. 30, 2014
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table presents the combined activity of stock options issued for the reporting periods ended September 30, 2014 as follows:
	Stock Options		Number of	Weighted		Weighted		Aggregate
			Shares	Average		Average		Intrinsic
				Exercise Price		Remaining		Value ($)
				per share ($)		Contractual
						Term (years)
	Outstanding at June 30, 2014		535,715	0.35		1.23		2,094,643
	Granted		-	-		-		-
	Exercised		-	-		-		-
	Expired		-	-		-		-
	Canceled		-	-		-		-
	Outstanding at September 30,2014		535,715	0.35		0.98		1,451,780
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	As of September 30, 2014 there was no unrecognized compensation cost.
	Stock Warrants
	Stock Warrants	Number of		Weighted		Weighted			Aggregate
		Shares		Average		Average			Intrinsic Value
				Exercise		Remaining			($)
				Price		Contractual Term
				per share		(years)
				($)
	Outstanding at June 30, 2014		8,894,355		5.01		2.78			2,278,458
	Granted		17,148		4.18		3.88			-
	Exercised		1,926,656		-		-			-
	Expired		1,059,616		-		-			-
	Canceled		-		-		-			-
	Outstanding at September 30,2014		5,925,231		5.15		3.86			113,571

Organization_and_Nature_of_Bus1

Organization and Nature of Business (Details Textual) (USD $)	0 Months Ended	3 Months Ended	113 Months Ended
	Feb. 15, 2010	Sep. 30, 2014	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013
Organization and Nature of Business [Line Items]
Entity Incorporation, State Country Name		Colorado
Entity Incorporation, Date Of Incorporation		25-Jul-00
Business Acquisition, Name of Acquired Entity		Edot-com.com, Inc.
Business Acquisition, Date of Acquisition Agreement		12-May-05
Common stock, shares issued		56,535,135	56,535,135	54,620,993
Common stock, shares, outstanding		56,535,135	56,535,135	54,620,993
Convertible Preferred Stock, Terms of Conversion		Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition.
Stockholders' Equity, Reverse Stock Split	(adjusted for the 3.5 to 1 reverse split)
ECMM [Member]
Organization and Nature of Business [Line Items]
Common Stock Shares Issued Prorata Basis			4,000
Stock Issued During Period, Shares, New Issues			80,000,000
Common stock, shares issued		100,000,000	100,000,000
Common stock, shares, outstanding		100,000,000	100,000,000
Business Acquisition, Percentage of Voting Interests Acquired		80.00%	80.00%
Series A Convertible Preferred Stock [Member]
Organization and Nature of Business [Line Items]
Stock Issued During Period, Shares, New Issues		187,000
Preferred stock, shares issued	2,000,000
Preferred stock	2,000	3,389	3,389		$2,990
Convertible Preferred Stock, Terms of Conversion		The Series A Preferred Stock is convertible, only upon sale or merger of the company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock

Restatement_of_Previously_Issu2

Restatement of Previously Issued Financial Statements (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Feb. 15, 2010
CURRENT ASSETS:
Cash and cash equivalents	$41,120,652	$36,696,892	$19,200,882	$13,923,245
Prepaid expenses	59,099	108,089	805,145
Prepaid expenses - related parties	424,402	709,221
Other current assets	0	150,000
Total Current Assets	41,604,153	37,664,202	20,006,027
PROPERTY AND EQUIPMENT
Property and equipment	7,299,254	6,736,742	3,779,636
Accumulated depreciation	-1,291,318	-1,239,986	-1,089,471
Property and equipment, net	6,007,936	5,496,756	2,690,165
TRADEMARK
Trademark	458,954	458,954	458,954
Accumulated amortization	-52,889	-50,696	-44,114
Trademark, net	406,065	408,258	414,840
SECURITY DEPOSIT	1,000,000	1,000,000	2,000,000
Total Assets	49,018,154	44,569,216	25,111,032
CURRENT LIABILITIES:
Accounts payable	155,978	376,446	408,058
Accounts payable - related parties	331,448	758,676	1,139,825
Accrued expenses	265,463	91,838	319,612
Total Current Liabilities	752,889	1,226,960	1,867,495
LONG TERM LIABILITIES:
Debentures payable	0	5,000,000	3,603,554
Derivative Liability			7,888,736
Total Long Term Liabilities	16,076,149	19,972,953	14,936,007
Total Liabilities	16,829,038	21,199,913	16,803,502
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERSb EQUITY:
Common stock	56,535	54,621	50,029
Additional paid-in capital	83,178,895	75,212,888	53,115,817
Accumulated deficit	-51,049,703	-51,901,400	-44,861,306
Total Stockholdersb Equity	32,189,116	23,369,303	8,307,530	8,009,652
Total Liabilities and Stockholdersb Equity	49,018,154	44,569,216	25,111,032
Warrant [Member]
LONG TERM LIABILITIES:
Derivative Liability	4,558,581	5,235,682	3,443,717
Series B Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	4,195,296	4,037,568
Derivative Liability	3,785,385	5,699,703
Series C Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	2,083,765	0
Derivative Liability	1,453,122	0
Scenario, Previously Reported [Member]
CURRENT ASSETS:
Cash and cash equivalents	41,120,652	36,696,892	19,200,882	13,923,245
Prepaid expenses	59,099		805,145
Prepaid expenses - related parties	424,402
Other current assets	0
Total Current Assets	41,604,153		20,006,027
PROPERTY AND EQUIPMENT
Property and equipment	7,299,254		3,779,636
Accumulated depreciation	-1,291,318		-1,089,471
Property and equipment, net	6,007,936		2,690,165
TRADEMARK
Trademark	458,954		458,954
Accumulated amortization	-52,889		-44,114
Trademark, net	406,065		414,840
SECURITY DEPOSIT	1,000,000		2,000,000
Total Assets	49,018,154		25,111,032
CURRENT LIABILITIES:
Accounts payable	155,978		408,058
Accounts payable - related parties	331,448		1,139,825
Accrued expenses	265,463		319,612
Total Current Liabilities	752,889		1,867,495
LONG TERM LIABILITIES:
Debentures payable			3,603,554
Derivative Liability			7,888,736
Total Long Term Liabilities	11,437,925		11,492,290
Total Liabilities	12,190,814		13,359,785
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERSb EQUITY:
Common stock	56,535		50,029
Additional paid-in capital	89,412,744		56,270,792
Accumulated deficit	-52,645,328		-44,572,564
Total Stockholdersb Equity	36,827,340		11,751,247
Total Liabilities and Stockholdersb Equity	49,018,154		25,111,032
Scenario, Previously Reported [Member] | Warrant [Member]
LONG TERM LIABILITIES:
Derivative Liability	0		0
Scenario, Previously Reported [Member] | Series B Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	4,195,296
Derivative Liability	3,785,385
Scenario, Previously Reported [Member] | Series C Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	3,457,244
Derivative Liability	0
Scenario, Adjustment [Member]
CURRENT ASSETS:
Total Current Assets	0
LONG TERM LIABILITIES:
Total Long Term Liabilities	4,638,224		3,443,717
Total Liabilities			3,443,717
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERSb EQUITY:
Additional paid-in capital	-6,233,849		-3,154,975
Accumulated deficit	1,595,625		-288,742
Total Stockholdersb Equity	-4,638,224		-3,443,717
Scenario, Adjustment [Member] | Warrant [Member]
LONG TERM LIABILITIES:
Derivative Liability	4,558,581		3,443,717
Scenario, Adjustment [Member] | Series C Debentures [Member]
LONG TERM LIABILITIES:
Debentures payable	-1,373,479
Derivative Liability	1,453,122
Series A Preferred Stock [Member]
STOCKHOLDERSb EQUITY:
Preferred Stock	3,389		2,990		2,000
Total Stockholdersb Equity	3,389	3,194		2,990
Series A Preferred Stock [Member] | Scenario, Previously Reported [Member]
STOCKHOLDERSb EQUITY:
Preferred Stock	3,389		2,990
Series B Preferred Stock [Member]
STOCKHOLDERSb EQUITY:
Preferred Stock	0		0
Total Stockholdersb Equity	0	0		0
Series B Preferred Stock [Member] | Scenario, Previously Reported [Member]
STOCKHOLDERSb EQUITY:
Preferred Stock	0		0
Series C Preferred Stock [Member]
STOCKHOLDERSb EQUITY:
Preferred Stock	0		0
Total Stockholdersb Equity	0	0		0
Series C Preferred Stock [Member] | Scenario, Previously Reported [Member]
STOCKHOLDERSb EQUITY:
Preferred Stock	$0		$0

Restatement_of_Previously_Issu3

Restatement of Previously Issued Financial Statements (Details 1) (USD $)	3 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
OPERATING EXPENSES
Research and development	$811,107	$1,174,221
Refund credit research and development costs	0	0
General and administrative	876,026	714,561
Total operating expenses	1,687,133	1,888,782
LOSS FROM OPERATIONS	-1,687,133	-1,888,782
OTHER INCOME (EXPENSE):
Interest income, net	39,323	9,560
Interest expense	-245,000	-120,986
Discount on convertible debentures	-273,218	-135,481
Beneficial conversion feature of convertible debentures	0	0
Change in fair market value of derivatives	3,017,725	-4,425,833
Other income (expense), net	2,538,830	-4,672,740
LOSS BEFORE INCOME TAXES	851,697	-6,561,522
INCOME TAX PROVISION	0	0
NET INCOME (LOSS)	851,697	-6,561,522	-14,106,474
NET INCOME (LOSS) PER COMMON SHARE - BASIC AND DILUTED (in dollars per share)	$0.02	($0.14)
Weighted average common shares outstanding - basic and diluted (in shares)	55,576,200	47,672,029
Scenario, Previously Reported [Member]
OPERATING EXPENSES
Research and development	811,107	1,174,221
Refund credit research and development costs	0	0
General and administrative	876,026	714,561
Total operating expenses	1,687,133	1,888,782
LOSS FROM OPERATIONS	-1,687,133	-1,888,782
OTHER INCOME (EXPENSE):
Interest income, net	39,323	9,560
Interest expense	-245,000	-120,986
Discount on convertible debentures	-260,578	-135,481
Beneficial conversion feature of convertible debentures	0	0
Change in fair market value of derivatives	1,914,318	-4,137,091
Other income (expense), net	1,448,063	-4,383,998
LOSS BEFORE INCOME TAXES	-239,070	-6,272,780
INCOME TAX PROVISION	0	0
NET INCOME (LOSS)	-239,070	-6,272,780
NET INCOME (LOSS) PER COMMON SHARE - BASIC AND DILUTED (in dollars per share)	($0.00)	($0.13)
Weighted average common shares outstanding - basic and diluted (in shares)	55,576,200	47,672,029
Restatement Adjustment [Member]
OPERATING EXPENSES
Total operating expenses		0
LOSS FROM OPERATIONS		0
OTHER INCOME (EXPENSE):
Discount on convertible debentures	-12,640
Beneficial conversion feature of convertible debentures
Change in fair market value of derivatives	1,103,407	-288,742
Other income (expense), net	1,090,767	-288,742
LOSS BEFORE INCOME TAXES	1,090,767	-288,742
INCOME TAX PROVISION		0
NET INCOME (LOSS)	$1,090,767	($288,742)	$504,858

Restatement_of_Previously_Issu4

Restatement of Previously Issued Financial Statements (Details 2) (USD $)	3 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$851,697	($6,561,522)	($14,106,474)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Preferred shares issued for license		0
Series A Preferred shares issued as compensation	72,980	0
Common shares and warrants issued for services	38,250	32,250
Common shares issued for interest
Warrants granted to scientific advisory board	22,292	106,050
Amortization of deferred compensation
Depreciation	51,332	52,719
Amortization	2,193	2,193
Change in fair value of derivative liability	-3,017,725	4,425,833
Amortization of deferred financing expenses	0
Discount convertible debentures	273,218	135,481
Beneficial conversion feature of convertible debentures	0	0
Changes in operating assets and liabilities:
Prepaid expenses	48,990	-206,765
Prepaid expenses - Related parties	284,819
Other current assets	150,000	0
Deferred expenses
Accounts payable - trade	-220,468	144,802
Accounts payable - related parties	-427,228	429,258
Accrued expenses	173,625	115,253
Accrued payroll to officers and related payroll tax expense
NET CASH USED IN OPERATING ACTIVITIES	-1,696,025	-1,324,448
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposit	0	-1,000,000
Purchase of property and equipment	-562,512	-2,273,989
Purchase of trademark	0
NET CASH USED IN INVESTING ACTIVITIES	-562,512	-3,273,989
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs		9,690,450
Proceeds from exercise of stock options
Proceeds from exercise of warrants	6,682,297	185,624
Collection of stock subscriptions received
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,682,297	9,876,074
NET CHANGE IN CASH	4,423,760	5,277,637
Cash at beginning of period	36,696,892	13,923,245	13,923,245
Cash at end of period	41,120,652	19,200,882	36,696,892
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	0	0
Income tax paid	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common stock issued for services rendered	38,250	32,250
Common stock for interest
Preferred stock issued as compensation	72,980	0
Series A Preferred stock issued as discount on Debentures	1,645,606
Stock options issued to the officers as compensation
Stock warrants granted to scientific advisory board	22,292	106,050
Stock warrants granted to brokers		113,696
Series B Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures
Series C Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures
Scenario, Previously Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	-239,070	-6,272,780
Adjustments to reconcile net income (loss) to net cash used in operating activities
Preferred shares issued for license
Series A Preferred shares issued as compensation	72,980
Common shares and warrants issued for services	38,250	32,250
Common shares issued for interest
Warrants granted to scientific advisory board	22,292	106,050
Amortization of deferred compensation
Depreciation	51,332	52,719
Amortization	2,193	2,193
Change in fair value of derivative liability	-1,914,318	4,137,091
Discount convertible debentures	260,578	135,481
Beneficial conversion feature of convertible debentures	0	0
Changes in operating assets and liabilities:
Prepaid expenses	48,990	-206,765
Prepaid expenses - Related parties	284,819
Other current assets	150,000
Deferred expenses
Accounts payable - trade	-220,468	144,802
Accounts payable - related parties	-427,228	429,258
Accrued expenses	173,625	115,253
Accrued payroll to officers and related payroll tax expense
NET CASH USED IN OPERATING ACTIVITIES	-1,696,025	-1,324,448
CASH FLOWS FROM INVESTING ACTIVITIES:
Security deposit	0	-1,000,000
Purchase of property and equipment	-562,512	-2,273,989
Purchase of trademark	0
NET CASH USED IN INVESTING ACTIVITIES	-562,512	-3,273,989
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs		9,690,450
Proceeds from exercise of stock options
Proceeds from exercise of warrants	6,682,297	185,624
Collection of stock subscriptions received
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,682,297	9,876,074
NET CHANGE IN CASH	4,423,760	5,277,637
Cash at beginning of period	36,696,892	13,923,245	13,923,245
Cash at end of period	41,120,652	19,200,882
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	0	0
Income tax paid	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common stock issued for services rendered	38,250	32,250
Common stock for interest
Preferred stock issued as compensation	72,980
Series A Preferred stock issued as discount on Debentures	1,645,606
Stock options issued to the officers as compensation
Stock warrants granted to scientific advisory board	22,292	106,050
Stock warrants granted to brokers		113,696
Scenario, Previously Reported [Member] | Series B Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures
Scenario, Previously Reported [Member] | Series C Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures
Restatement Adjustment [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	1,090,767	-288,742	504,858
Adjustments to reconcile net income (loss) to net cash used in operating activities
Preferred shares issued for license
Common shares issued for interest
Amortization of deferred compensation
Change in fair value of derivative liability	-1,103,407	288,742
Discount convertible debentures	12,640
Beneficial conversion feature of convertible debentures
Changes in operating assets and liabilities:
Deferred expenses
Accrued payroll to officers and related payroll tax expense
NET CASH USED IN OPERATING ACTIVITIES	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
NET CASH USED IN INVESTING ACTIVITIES		0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs
Proceeds from exercise of stock options
Collection of stock subscriptions received
NET CHANGE IN CASH	0
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common stock for interest
Stock options issued to the officers as compensation
Restatement Adjustment [Member] | Series B Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures
Restatement Adjustment [Member] | Series C Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures

Restatement_of_Previously_Issu5

Restatement of Previously Issued Financial Statements (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
Additional Paid In Capital	$83,178,895	$53,115,817	$75,212,888
Retained Earnings (Accumulated Deficit)	-51,049,703	-44,861,306	-51,901,400
Net Income (Loss) Attributable To Parent	851,697	-6,561,522	-14,106,474
Series C Preferred Values Issued for Debenture Interest	3,031,125
Series A Preferred Values Issued As Interest	1,152,297
Series A Preferred Values Issued Fair Value	1,879,428
Long-Term Debentures Payable [Member]
Interest Expense, Debt	115,490
Restatement Adjustment [Member]
Additional Paid In Capital			5,235,682
Retained Earnings (Accumulated Deficit)			504,858
Net Income (Loss) Attributable To Parent	1,090,767	-288,742	504,858
Scenario, Previously Reported [Member]
Additional Paid In Capital	89,412,744	56,270,792
Retained Earnings (Accumulated Deficit)	-52,645,328	-44,572,564
Net Income (Loss) Attributable To Parent	-239,070	-6,272,780
Debt Instrument, Unamortized Discount (Premium), Net	$1,373,479

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,460,946	6,922,395
Employee Stock Option [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,715	535,715
Total Stock Option [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,715	535,715
Warrants Issued One [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	513,143
Warrants Issued Two [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	466,486
Warrants Issued Three [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	211,429	211,429
Warrants Issued Four [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	568,771
Warrants Issued Five [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,437,871
Warrants Issued Six [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	65,714	65,714
Warrants Issued Seven [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,571	68,571
Warrants Issued Eight [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	68,571	68,571
Warrants Issued Nine [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,810,071	2,910,071
Warrants Issued Ten [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143	17,143
Warrants Issued Eleven [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58,910	58,910
Warrants Issued Twelve [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143
Warrants Issued Thirteen [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,479,935
Warrants Issued Fourteen [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	76,306
Warrants Issued Fifteen [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,143
Warrants Issued Sixteen [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,148
Warrants Issued Seventeen [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,148
Total Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,925,231	6,386,680

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014
Accounting Policies [Line Items]
Common Stock, Par Or Stated Value Per Share	$0.00	$0.00
Debt Conversion, Converted Instrument, Shares Issued	1,960,785
Debt Interest Conversion Converted Instrument Shares Issued	1,142,858
Warrants Exercise Price	$6.05
Convertible Preferred Stock, Terms Of Conversion	Only in the event of a “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A “change of control” is defined as an event in which the Company’s shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition.
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Preferred Stock, Shares Issued	3,387,795	3,193,079
Common Stock [Member]
Accounting Policies [Line Items]
Common Stock, Par Or Stated Value Per Share	$3.06
Convertible Preferred Stock, Shares Issued upon Conversion	11,857,283
September 23, 2005 [Member]
Accounting Policies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$0.35
Share Based Compensation Arrangement By Share Based Payment Award Expiration Term	10 years
June 15,2006 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$3.50
Warrants Expiration Date	15-Aug-14
August 22, 2008 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$3.50
Warrants Expiration Date	15-Aug-14
June 15, 2008 [Member]
Accounting Policies [Line Items]
Warrants Expiration Date	28-Feb-15
June 30, 2009 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$3.50
Warrants Expiration Date	15-Aug-14
September 30, 2009 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$3.50
Warrants Expiration Date	15-Aug-14
August 16 2010 [Member]
Accounting Policies [Line Items]
Warrants Expiration Date	30-Jun-15
August 16 2011 [Member]
Accounting Policies [Line Items]
Warrants Expiration Date	30-Jun-16
August 16 2012 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$5.17
Warrants Expiration Date	30-Jun-17
September 10, 2013 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$5.25
Warrants Expiration Date	10-Sep-18
September 10, 2013 [Member] | Placement Agents [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$5.25
Warrants Expiration Date	10-Sep-18
August 15, 2013 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$5.17
Warrants Expiration Date	15-Aug-17
November 15, 2013 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$6.56
Warrants Expiration Date	15-Nov-17
January 24, 2014 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$6.05
Warrants Expiration Date	24-Jan-19
January 24, 2014 [Member] | Placement Agents [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$5.25
Warrants Expiration Date	24-Jan-19
February 14, 2014 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$3.98
Warrants Expiration Date	14-Feb-18
May 15, 2014 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$4.11
Warrants Expiration Date	15-May-18
August 15 2014 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$5.02
Warrants Expiration Date	15-Aug-18
Minimum [Member] | June 15, 2008 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$2.45
Minimum [Member] | August 16 2010 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$5.15
Minimum [Member] | August 16 2011 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$2.80
Maximum [Member] | June 15, 2008 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$9.38
Maximum [Member] | August 16 2010 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$6.34
Maximum [Member] | August 16 2011 [Member]
Accounting Policies [Line Items]
Warrants Exercise Price	$4.94

Financial_Condition_Details_Te

Financial Condition (Details Textual) (USD $)	0 Months Ended		3 Months Ended
	Jul. 02, 2014	Sep. 05, 2014	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Jul. 17, 2014
Financial Condition [Line Items]
Cash and cash equivalents			$41,120,652	$36,696,892	$19,200,882	$13,923,245
Common stock, par value (in dollars per share)			$0.00	$0.00
Long-Term Debt, Excluding Current Maturities			0	5,000,000	3,603,554
Class of Warrant or Right, Exercise Price of Warrants or Rights			$1
Retained Earnings (Accumulated Deficit)			-51,049,703	-51,901,400	-44,861,306
Derivative, Description of Terms	The Company has the right, but not the obligation, to repay the Debenture prior to the Maturity Date (the Redemption Payment) in cash or, at the option of the Holder, a number of shares of the Companys Common Stock. If the closing bid price of the Common Stock is in excess of $5.25 when the Company notifies the Holder it has elected to prepay the Debenture (the Redemption Date), the Company must redeem the Debenture by delivering to the Holder 951,381 shares of Common Stock and any unpaid coupon interest in lieu of a cash Redemption Payment. If the Holder elects to receive the Redemption Payment in cash, or if the closing bid price of the Common Stock is less than $5.25, the Company shall pay to the Holder a Redemption Payment in cash equal to the principal amount of the Debenture, plus any accrued coupon interest, and additional interest of 7% per annum for the period from the Closing Date to the Redemption Date. As additional interest on the Debenture, the Company shall issue 187,000 shares of its restricted Series A Preferred Stock (the Series A) to the Holder. Each shares of Series A votes at 9 votes per share. In addition, only in the event of a change of control of the Company, each Series A preferred share is convertible to 3.5 shares of its new common stock. A change of control is defined as an event in which the Companys shareholders become 60% or less owners of a new entity as a result of a change of ownership, merger or acquisition. In the absence of a change of control event, the Series A stock is not convertible into Common Stock, and does not carry any dividend rights or any other financial effects. The Offering was conducted directly by the Company without the use of a placement agent. Accordingly, no placement agent fees or other commissions were paid by the Company in connection with the Offering.
Registered Warrants [Member]
Financial Condition [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,136,655	2,136,655
Class of Warrant or Right, Exercise Price of Warrants or Rights		$3.50
Proceeds from Warrant Exercises		7,478,292.50	7,478,292.50
Class of Warrant or Right, Outstanding		3,071,986					3,071,986
Long-Term Debentures Payable [Member]
Financial Condition [Line Items]
Long-Term Debt, Excluding Current Maturities				5,000,000
Derivative, Cap Interest Rate	10.00%
Debt Instrument, Maturity Date			30-Jun-18
Long-Term Debentures Payable [Member] | Director [Member]
Financial Condition [Line Items]
Common stock, par value (in dollars per share)			$0.00
Debt Instrument, Convertible, Conversion Price			$5.25
Long-Term Debt, Excluding Current Maturities			$5,000,000
Derivative, Cap Interest Rate			10.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$3.50

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
Research and development	$811,107	$1,174,221
Due to Related Parties	9,000,000		9,000,000
Director [Member] | Long-Term Debentures Payable [Member]
Due to Related Parties, Noncurrent	4,000,000	4,000,000	4,000,000
Payments to Fund Long-term Loans to Related Parties	0		0
Due to Related Parties, Noncurrent	4,000,000		4,000,000
Director [Member] | Long-Term Debentures Payable [Member] | Subsequent Event [Member]
Due to Related Parties, Noncurrent	5,000,000	5,000,000	5,000,000
Payments to Fund Long-term Loans to Related Parties	0		0
Due to Related Parties, Noncurrent	5,000,000		5,000,000
Innohaven, LLC [Member]
Due from Related Parties	0		4,500,000
TheraCour Pharma, Inc [Member]
Due from Related Parties	110,578		528,000
Net Account Payable to related party	331,448		758,676
Research and development	$769,185	$924,125

Related_Party_Transactions_Det1

Related Party Transactions (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Jul. 02, 2014	Jun. 30, 2013
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
Lab Supplies and Chemicals Fees	$25,000
Other General and Administrative Expense	2,000
Royalty Payment Percentage Of Net Sales	15.00%
Security Deposit	1,000,000	1,000,000	2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1
Long-Term Debt, Excluding Current Maturities	0	5,000,000	3,603,554
Common Stock, Par Or Stated Value Per Share	$0.00	$0.00
Long-Term Debentures Payable [Member]
Related Party Transaction [Line Items]
Long-Term Debt, Excluding Current Maturities		5,000,000
Derivative, Cap Interest Rate				10.00%
Long-Term Debentures Payable [Member] | Director [Member]
Related Party Transaction [Line Items]
Due to Related Parties, Noncurrent	4,000,000	4,000,000			4,000,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Interest Rate Terms	The debentures bear an interest rate of 8% p.a., an additional interest payable in restricted common stock of 0.33, 0.33, and 0.34 shares in year 1, 2, and 3 respectively, and an additional interest of 0.33 warrants to be issued in the fourth year, per $1 of principal.
Class of Warrant or Right, Exercise Price of Warrants or Rights	$3.50
Debt Instrument, Term	3 years
Debt Instrument, Basis Spread on Variable Rate	7.00%
Long-Term Debt, Excluding Current Maturities	5,000,000
Derivative, Cap Interest Rate	10.00%
Common Stock, Par Or Stated Value Per Share	$0.00
Debt Instrument, Convertible, Conversion Price	$5.25
Long-Term Debentures Payable [Member] | Director [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Due to Related Parties, Noncurrent	5,000,000	5,000,000			5,000,000
Long-Term Debt, Excluding Current Maturities	5,000,000
Derivative, Cap Interest Rate	10.00%
Common Stock, Par Or Stated Value Per Share	$0.00
Debt Instrument, Convertible, Conversion Price	$5.25
TheraCour Pharma, Inc [Member]
Related Party Transaction [Line Items]
Security Deposit	$424,402

Concentrations_Details

Concentrations (Details) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Net Purchases	$1,687,133	$1,888,782
Accounts Payable	487,426	1,547,883
Supplier Concentration Risk [Member] | TheraCour Pharma, Inc [Member]
Concentration Risk [Line Items]
Net Purchases	769,185	924,126
Accounts Payable	331,448	1,139,825
Supplier Concentration Risk [Member] | Kard Scientific Inc [Member]
Concentration Risk [Line Items]
Net Purchases	0	247,660
Accounts Payable	$123,570	$246,963
Net Purchases [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	100.00%	100.00%
Net Purchases [Member] | TheraCour Pharma, Inc [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	45.60%	48.90%
Net Purchases [Member] | Kard Scientific Inc [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	0.00%	13.10%
Accounts Payable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	100.00%	100.00%
Accounts Payable [Member] | TheraCour Pharma, Inc [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	68.00%	73.60%
Accounts Payable [Member] | Kard Scientific Inc [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	25.40%	16.00%

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]
GMP Facility	$3,551,713	$3,099,780
Office Equipment	30,048	30,048
Furniture and Fixtures	1,400	1,400
Lab Equipment	3,716,093	3,605,514
Total Property and Equipment	7,299,254	6,736,742	3,779,636
Less Accumulated Depreciation	-1,291,318	-1,239,986	-1,089,471
Property and Equipment, Net	$6,007,936	$5,496,756	$2,690,165

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$51,332	$52,719

Trademark_and_Patents_Details

Trademark and Patents (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013
Trademarks And Patents [Line Items]
Trademarks and Patents	$458,954	$458,954	$458,954
Less Accumulated Amortization	-52,889	-50,696	-44,114
Trademarks and Patents, Net	$406,065	$408,258

Trademark_and_Patents_Details_

Trademark and Patents (Details Textual) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Trademarks And Patents [Line Items]
Amortization	$2,193	$2,193

Prepaid_Expenses_Details

Prepaid Expenses (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
Prepaid Expense	$483,501	$817,310
Prepaid Others	59,099	108,089
TheraCour Pharma, Inc [Member]
Prepaid Expense	$424,402	$709,221

Equity_Transactions_Details

Equity Transactions (Details)	0 Months Ended
	Aug. 15, 2014
Class of Stock [Line Items]
Expected life (year)	4 years
Expected volatility	91.68%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	1.20%

Equity_Transactions_Details_Te

Equity Transactions (Details Textual) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended	0 Months Ended
	Aug. 15, 2014	Sep. 09, 2013	Aug. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2014	Dec. 31, 2014	Sep. 05, 2014	Jul. 02, 2014	Jul. 17, 2014
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants			17,148
Stock Issued During Period Price Per Share			$5.02
Fair Value Of Common Stock Warrant Issued During Period For Consulting Services			$22,292
Warrants expiration period			August, 2018
Stockholders Equity Note, Stock Split, Conversion Ratio		3.5
Class of Warrant or Right, Exercise Price of Warrants or Rights				$1		1
Debt Conversion, Converted Instrument, Shares Issued				1,960,785
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	91.68%
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed				0.00%
Debt Instrument, Redemption Price, Percentage				0.00%
Fair Value Assumptions, Risk Free Interest Rate				21.86%
Embedded Derivative, Loss on Embedded Derivative				1,879,428
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years
Embedded Derivative Financial Instruments [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					92.00%	85.00%	75.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				1 year
Discount On Convertible Debentures [Member]
Class of Stock [Line Items]
Servicing Liability at Amortized Cost, Amortization				115,490
Long-Term Debentures Payable [Member]
Class of Stock [Line Items]
Long-term Debt				5,000,000		5,000,000			5,000,000
Derivative, Cap Interest Rate									10.00%
Servicing Liability at Amortized Cost, Amortization				3,031,125
Registered Warrants [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				2,136,655		2,136,655		2,136,655
Class of Warrant or Right, Outstanding								3,071,986		3,071,986
Class of Warrant or Right, Exercise Price of Warrants or Rights								$3.50
Proceeds from Warrant Exercises				7,478,292.50				7,478,292.50
Minimum [Member]
Class of Stock [Line Items]
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed				1.00%
Debt Instrument, Redemption Price, Percentage				1.00%
Pre-Split Stock Price Per Share				$0.78		0.7771
Maximum [Member]
Class of Stock [Line Items]
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed				10.00%
Debt Instrument, Redemption Price, Percentage				5.00%
Pre-Split Stock Price Per Share				$0.86		0.8571
Preferred Series A shares [Member]
Class of Stock [Line Items]
Fair Value Measurements, Significant Assumptions				a. The common stock price (post-reverse split) was in the range $3.90 to $4.16; b. 54,614,930 to 56,450,000 shares outstanding and Series A Preferred shares with 2,572 (postsplit 9/10/13) issued monthly ; c. A 5.36% premium over the common shares for the voting preferences; d. 63,899,777 to 65,193,001 total voting shares and the monthly shares representing voting rights of 2.425% to 2.448% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 and a remaining restricted term of 2.59 to 2.42 years; f. 35.53% to 31.95% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 87.68% to 91.87% volatility, 0.47% to 0.58% risk free rate) applied to the converted common.
Director [Member] | Long-Term Debentures Payable [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$3.50		3.5
Derivative, Cap Interest Rate				10.00%		10.00%
Consulting Services [Member]
Class of Stock [Line Items]
Shares issued to a Director for services rendered (in shares)				2,059
Stock Issued During Period, Value, Issued For Services				27,000
Director Services [Member]
Class of Stock [Line Items]
Shares issued to a Director for services rendered (in shares)				2,856
Stock Issued During Period, Value, Issued For Services				11,250
Subsequent Event [Member] | Director [Member] | Long-Term Debentures Payable [Member]
Class of Stock [Line Items]
Derivative, Cap Interest Rate				10.00%		10.00%
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross				7,716
Stock Issued During Period, Value, Share-based Compensation, Gross				72,980
Series A Convertible Preferred Stock [Member] | Long-Term Debentures Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Converted Instrument, Shares Issued				187,000					187,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues				187,000
Stock Issued During Period, Value, New Issues				$1,152,297

Stock_Options_and_Warrants_Det

Stock Options and Warrants (Details) (Equity Option [Member], USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	535,715
Number of Shares, Granted	0
Number of Shares, Exercised	0
Number of Shares, Expired	0
Number of Shares, Canceled	0
Number of Shares, Outstanding	535,715	535,715
Weighted Average Exercise Price per share , Outstanding	$0.35
Weighted Average Exercise Price per share, Granted	$0
Weighted Average Exercise Price per share, Exercised	$0
Weighted Average Exercise Price per share, Expired	$0
Weighted Average Exercise Price per share, Canceled	$0
Weighted Average Exercise Price per share , Outstanding	$0.35	$0.35
Weighted Average Remaining Contractual Term, (year) Outstanding	11 months 23 days	1 year 2 months 23 days
Aggregate Intrinsic Value, Outstanding	$2,094,643
Aggregate Intrinsic Value, Outstanding	$1,451,780	$2,094,643

Stock_Options_and_Warrants_Det1

Stock Options and Warrants (Details 1) (Stock Warrants [Member], USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	8,894,355
Number of Shares, Granted	17,148
Number of Shares, Exercised	1,926,656
Number of Shares, Expired	1,059,616
Number of Shares, Canceled	0
Number of Shares, Outstanding	5,925,231	8,894,355
Weighted Average Exercise Price per share , Outstanding	$5.01
Weighted Average Exercise Price per share, Granted	$4.18
Weighted Average Exercise Price per share, Exercised	$0
Weighted Average Exercise Price per share, Expired	$0
Weighted Average Exercise Price per share, Canceled	$0
Weighted Average Exercise Price per share , Outstanding	$5.15	$5.01
Weighted Average Remaining Contractual Term, (year) Granted	3 years 10 months 17 days
Weighted Average Remaining Contractual Term, (year) Outstanding	3 years 10 months 10 days	2 years 9 months 11 days
Aggregate Intrinsic Value, Outstanding	$2,278,458
Aggregate Intrinsic Value, Outstanding	$113,571	$2,278,458

Stock_Options_and_Warrants_Det2

Stock Options and Warrants (Details Textual) (USD $)	12 Months Ended	3 Months Ended	1 Months Ended
	Jun. 30, 2009	Sep. 30, 2014	Sep. 30, 2005	16-May-07
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$7,044
June 30, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable		277,143
Warrants Expiration Date		30-Jun-15
June 30, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable		68,571
Warrants Expiration Date		30-Jun-16
June 30, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable		68,571
Warrants Expiration Date		30-Jun-17
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable		5,383,460
Warrants Expiration Date		30-Jun-19
June 30 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable		127,487
Warrants Expiration Date		30-Jun-18
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			142,857
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number			71,429
President [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			285,715
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number			95,238
Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			142,857
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number			71,429	107,143

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	3 Months Ended		1 Months Ended	0 Months Ended
	Feb. 28, 2011	Sep. 30, 2014	Sep. 30, 2013	Sep. 17, 2013	Feb. 11, 2013
	sqft				sqft
Commitments and Contingencies [Line Items]
Space For Office and Laboratory	7,000
Monthly Base Rent	$8,695
Lease Expiration Date	28-Feb-11
Operating Leases, Rent Expense, Net		26,085	26,085
Cash Collateral for Borrowed Securities					1,000,000
Debt Instrument, Annual Principal Payment					2,000,000
Fixtures And Improvements		4,500,000
Litigation Settlement, Expense		150,000
TheraCour Pharma, Inc [Member]
Commitments and Contingencies [Line Items]
Cash Collateral for Borrowed Securities					1,000,000
Inno Haven [Member]
Commitments and Contingencies [Line Items]
Operating Leases, Rent Expense, Net		0			0
Area of Land					18,000
Cash Collateral for Borrowed Securities				2,000,000	2,000,000
Securities Received as Collateral				$1,000,000
Securities Owned and Pledged as Collateral, Description				The value of the Collateral Shares shall be determined every three months and, in the event that the current number of shares of the Common Stock is less than $1,000,000, Inno-Haven may deposit, and the Company shall register, additional shares to equal the aforesaid $1,000,000. Alternatively, Inno-Haven may deposit cash equal to the difference between $1,000,000 and the value of the Collateral Shares.

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	1 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2014
Subsequent Event [Member]
Subsequent Event [Line Items]
Registration Of Securities, Value	$50
Issuance Of Securities, Post Effective Registration Statement, Value	$50